

Clinical Guide to **Nutrition Care in Kidney Disease**

THIRD EDITION

Renal Practice Group

National Kidney Foundation Council on Renal Nutrition

Editors: Janelle E. Gonyea, RDN, LD, FNKF, and Stacey C. Phillips, MS, RDN

**eat
right.** Academy of Nutrition
and Dietetics

Academy of Nutrition and Dietetics
120 S. Riverside Plaza, Suite 2190
Chicago, IL 60606

Clinical Guide to Nutrition Care in Kidney Disease, Third Edition

ISBN 978-0-88091-201-3 (print)

ISBN 978-0-88091-073-6 (eBook)

Catalog Number 344423 (print)

Catalog Number 344423e (eBook)

Copyright © 2023, Academy of Nutrition and Dietetics. All rights reserved. Except for brief quotations embodied in critical articles or reviews, no part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior written consent of the publisher.

The views expressed in this publication are those of the authors and do not necessarily reflect policies and/or official positions of the Academy of Nutrition and Dietetics. Mention of product names in this publication does not constitute endorsement by the authors or the Academy of Nutrition and Dietetics. The Academy of Nutrition and Dietetics disclaims responsibility for the application of the information contained herein.

10 9 8 7 6 5 4 3 2 1

For more information on the Academy of Nutrition and Dietetics, visit www.eatright.org.

Library of Congress Cataloging-in-Publication Data

Names: Phillips, Stacey, editor. | National Kidney Foundation. Council on Renal Nutrition, editor.

Title: Clinical guide to nutrition care in kidney disease / Renal Practice Group, National Kidney Foundation Council on Renal Nutrition ; editors, Stacey Phillips, MS, RD, and Janelle Gonyea, RDN, LD.

Description: Third edition. | Chicago, IL : Academy of Nutrition and Dietetics, [2022] | Includes bibliographical references and index.

Identifiers: LCCN 2022020485 (print) | LCCN 2022020486 (ebook) | ISBN 9780880910736 (paperback) | ISBN 9780880912013 (ebook)

Subjects: LCSH: Kidneys--Diseases--Nutritional aspects. | Kidneys--Diseases--Diet therapy.

Classification: LCC RC903 .C5585 2022 (print) | LCC RC903 (ebook) | DDC 616.6/10654--dc23/eng/20220713

LC record available at <https://lccn.loc.gov/2022020485>

LC ebook record available at <https://lccn.loc.gov/2022020486>

Contents

Frequently Used Terms and Abbreviations	v
About the Editors	vii
Contributors	ix
Reviewers	xi
Preface	xiv
Acknowledgements	xv
SECTION I OVERVIEW OF KIDNEY DISEASE AND NUTRITION ASSESSMENT	
CHAPTER 1 Overview: Pathophysiology of the Kidney	1
CHAPTER 2 Nutrition Assessment in Chronic Kidney Disease	8
SECTION II NUTRITION MANAGEMENT OF KIDNEY DISEASE	
CHAPTER 3 Nutrition Management in Chronic Kidney Disease Stages 1 Through 5	33
CHAPTER 4 Nutrition Management in Acute Kidney Injury	49
CHAPTER 5 Nutrition Management of the Adult Patient on In-Center Hemodialysis	65
CHAPTER 6 Nutrition Management of the Adult Patient on Home Hemodialysis	79
CHAPTER 7 Nutrition Management of the Adult Patient on Peritoneal Dialysis	87
CHAPTER 8 Nutrition Management of the Adult Kidney Transplant Patient	111
SECTION III OTHER CONDITIONS AND SPECIAL POPULATIONS WITH KIDNEY DISEASE	
CHAPTER 9 Nutrition Management of Diabetes in Chronic Kidney Disease	139
CHAPTER 10 Mineral and Bone Disorders and Kidney Disease	185
CHAPTER 11 Cardiovascular Disease and Kidney Disease	223
CHAPTER 12 Pregnancy and Chronic Kidney Disease	236
CHAPTER 13 Kidney Disease in the Pediatric Patient	245
CHAPTER 14 Nutritional Management of Kidney Stones	289
SECTION IV NUTRITION SUPPORT WITH KIDNEY DISEASE	
CHAPTER 15 Enteral Nutrition and Kidney Disease	317
CHAPTER 16 Parenteral Nutrition and Kidney Disease	327

SECTION V MEDICATION AND SUPPLEMENT USE IN KIDNEY DISEASE

CHAPTER 17 Medications Commonly Prescribed in Kidney Disease 359
CHAPTER 18 Oral Nutrition Supplements in Kidney Disease 385
CHAPTER 19 Commonly Used Dietary Supplements in Patients With Kidney Disease 396

SECTION VI SPECIAL CONSIDERATIONS IN KIDNEY DISEASE NUTRITION CARE

CHAPTER 20 Guidelines for Patients Following Vegetarian, Vegan, or Plant-Based Diets
in Kidney Disease 431
CHAPTER 21 Emergency Meal Planning for Patients on Dialysis 437
CHAPTER 22 Kidney–Gut Axis: The Connection Between Kidney Disease and the Gut 443

SECTION VII PRACTICE RECOMMENDATIONS FOR NUTRITION CARE IN KIDNEY DISEASE

CHAPTER 23 Practice Guidelines, Reimbursement, Scope of Practice, and Continuous
Quality Improvement in Kidney Disease 455
CHAPTER 24 The Nutrition Care Process Model in Nephrology Nutrition 463
CHAPTER 25 Counseling and Communication Skills for the Renal Dietitian 470

Appendix: Resources for Kidney Disease 475
Continuing Professional Education 480
Index 481

SAMPLE Print
Not for Sale

Frequently Used Terms and Abbreviations

AACE	American Association of Clinical Endocrinologists	DKD	diabetic kidney disease
AADE	American Association of Diabetes Educators	DM	diabetes mellitus
ACC	American College of Cardiology	DN	diabetic neuropathy
ACE	angiotensin-converting enzyme	DPI	dietary protein intake
ADA	American Diabetes Association	DR	diabetic retinopathy
ADCES	Association of Diabetes Care & Education Specialists	DRI	Dietary Reference Intake
AF	atrial fibrillation	DXA	dual-energy x-ray absorptiometry
AGE	advanced glycation end	EASD	European Association for the Study of Diabetes
AHA	American Heart Association	EH	enteric hyperoxaluria
AKI	acute kidney injury	EN	enteral nutrition
AMDR	acceptable macronutrient distribution ranges	ESA	erythropoietin-stimulating agents
AN	autonomic neuropathy	ESKD	end-stage kidney disease
APD	automated peritoneal dialysis	FDA	US Food and Drug Administration
ARB	angiotensin II receptor blockers	FSGS	focal segmental glomerulosclerosis
ASPEN	American Society for Parenteral and Enteral Nutrition	GA	glycated albumin
AUA	American Urological Association	GAN	gastrointestinal autonomic neuropathy
BG	blood glucose	GDM	gestational diabetes mellitus
BIA	bioelectrical impedance analysis	GDP	glucose degradation products
BMD	bone mineral density	GFR	glomerular filtration rate
BMI	body mass index	GRV	gastric residual volume
BP	blood pressure	GV	glycemic variability
BUN	blood urea nitrogen	HCFC	high concentrated fructose corn
CAC	coronary artery calcification	HDL	high-density lipoprotein
CAD	coronary artery disease	HF	heart failure
CAN	cardiovascular autonomic neuropathy	HHD	home hemodialysis
CAPD	continuous ambulatory peritoneal dialysis	IBD	inflammatory bowel disease
CaSR	calcium-sensing receptors	IBW	ideal body weight
CCPD	continuous cyclic peritoneal dialysis	ICHD	in-center hemodialysis
CGM	continuous glucose monitoring	ICU	intensive care unit
CHD	coronary heart disease	IDWG	intradialytic weight gain
CHF	congestive heart failure	IFG	impaired fasting glucose
CKD	chronic kidney disease	IH	idiopathic hypercalcaemia
CRP	C-reactive protein	ILE	intravenous lipid emulsion
CRRT	continuous renal replacement therapy	INR	international normalized ratio
CT	computed tomography	IR	insulin resistance
CVD	cardiovascular disease	IRS	insulin resistance syndrome
DASH	Dietary Approaches to Stop Hypertension	ISRN	International Society of Renal Nutrition and Metabolism
		KDIGO	Kidney Disease Improving Global Outcomes

CLINICAL GUIDE TO NUTRITION CARE IN KIDNEY DISEASE

KDOQI	Kidney Disease Outcomes Quality Initiative	PTH	parathyroid hormone
KRT	kidney replacement therapy	PVD	peripheral vascular disease
LDL	low-density lipoprotein	RBC	red blood cell
LEA	lower-extremity amputation	RDN	registered dietitian nutritionist
LVH	left ventricular hypertrophy	RFS	refeeding syndrome
MBD	mineral bone disease	RKF	residual kidney function
MD	maintenance dialysis	RR	risk ratio
MI	myocardial infarction	RTA	renal tubular acidosis
MNT	medical nutrition therapy	SCCM	Society of Critical Care Medicine
MS	metabolic syndrome	SD	standard deviation
MUAC	mid-upper arm circumference	SDI	standard dietary intake
NFPE	nutrition focused physical exam	SDS	standard deviation scores
NHANES	National Health and Nutrition Examination Survey	SGA	subjective global assessment
NIPD	nocturnal intermittent peritoneal dialysis	SIADH	syndrome of inappropriate antidiuretic hormone
NODAT	new-onset diabetes after transplantation	SMBG	self-monitoring of blood glucose
NPH	neutral protamine Hagedorn	SO	soybean oil
OGTT	oral glucose tolerance test	SPS	sodium polystyrene sulfonate
ONS	oral nutrition supplements	TLC	therapeutic lifestyle change
PA	physical activity	TNA	total nitrogen appearance
PAD	peripheral artery disease	TPD	tidal peritoneal dialysis
PAL	physical activity level	TW	target weight
PCR	protein catabolic rate	UL	Tolerable Upper Intake Level
PD	peritoneal dialysis	USRDS	United States Renal Data System
PEG	percutaneous endoscopic gastrostomy	UTI	urinary tract infection
PET	peritoneal equilibration test	VC	vascular calcification
PH	primary hyperoxaluria	VDR	vitamin D receptor
PN	parenteral nutrition	VLDL	very low-density lipoprotein
PNA	protein equivalent of nitrogen appearance	WHI	Women's Health Initiative
PPN	peripheral parenteral nutrition	WHO	World Health Organization
PRAL	potential renal acid load	WHR	waist-to-hip ratio

About the Editors

Janelle E. Gonyea, RDN, LD, FNKF, received her dietetics degree from Michigan State University in East Lansing, MI, and completed her dietetic internship at Mayo Clinic Hospital, Saint Marys Campus in Rochester, MN. She has 30 years of experience as a renal dietitian at the Mayo Clinic in Rochester, MN, working with chronic kidney disease patients in all stages of their disease process and across all treatment options. In addition to patient care, she authored medical nutrition therapy (MNT) protocols, chaired committees in charge of developing patient education materials and programming for the Division of Nephrology and Hypertension receiving the Mayo Clinic Department of Medicine Outstanding Education Award and educated countless nephrology colleagues, medical students, nephrology fellows and dietetic interns, holding the rank of Assistant Professor of Nutrition for the Mayo Clinic College of Medicine.

In addition to her clinical dietitian role, Janelle has served on the executive committee of the Council on Renal Nutrition for the National Kidney Foundation as editor of the *RenalLink* professional council newsletter, planning committee chair for the annual Spring Clinical Meeting as well as coordinator for the preconference workshop. Janelle was recognized for her work with the Council on Renal Nutrition by receiving the Susan C. Knapp Excellence in Education Award and Outstanding Service Award. She has also authored numerous articles for patient and professional publications and often speaks at regional and national meetings on various topics related to renal nutrition. Janelle has volunteered as program content creator and reviewer for various patient and professional organizations and received the American Association of Kidney Patients Dietitian Medal of Excellence. Currently she serves as a committee member for the update of the Academy of Nutrition and Dietetics National Kidney Diet, on the Medical Review Committee for the Midwest Kidney Network, as a charter member of the American Kidney Fund's Dietitian Advisory Group and as coeditor for the American Association of Kidney Patients' *AAKP Delicious!* recipe series. Janelle has had a lifelong passion for all things related to nephrology and enjoys the opportunities she has been given to collaborate with others to promote patient advocacy and advancement of care for kidney disease.

Stacey C. Phillips, MS, RDN, has been a registered dietitian nutritionist for over 16 years working for Mercy Health Saint Mary's in Grand Rapids, MI. She received her undergraduate degree from the University of Illinois at Urbana-Champaign, completed her dietetic internship at the Mayo Clinic School of Health Sciences in Rochester, MN, and earned her master's degree in dietetics through Central Michigan University. In her role as a clinical dietitian, Stacey has worked with patients in all stages of chronic kidney disease including kidney transplant recipients and living kidney donors as well as in the areas of general medicine, older adult, oncology, and long-term acute care. Her interest in renal nutrition developed from enjoying this rotation during her own internship due to some dedicated preceptors and through her current work Stacey has mentored over 70 dietetic interns as they rotate through their older adult and renal nutrition rotations.

Outside of her clinical work, Stacey has been involved with the Renal Dietitians Dietetics Practice Group through the Academy of Nutrition and Dietetics in several different roles including the Renal Nutrition Forum Editorial Board, Treasurer, Awards Chair, and Marketing and Communications Chair and was recognized with

the 2021 Renal Dietitians Dietetics Practice Group Outstanding Service Award. She has served as coeditor of the American Association of Kidney Patients' *AAKP Delicious!* recipe series and was awarded the 2019 American Association of Kidney Patients Dietitian Medal of Excellence. In addition, Stacey has been a member of the National Kidney Foundation and served as the Patient Education Editor for the *Journal of Renal Nutrition*. Currently, she enjoys a number of consultant roles including as a subject matter expert for Dietitians on Demand, a Health Coach for the University of Michigan Controlling Hypertension Through Education and Coaching in Kidney Disease (CHECK-D) Study and as a nutrition reviewer for several different professional organizations. She is also a contributor to online medical information, peer-reviewed journals, and Academy of Nutrition and Dietetic publications. With each of these roles, Stacey has enjoyed working with a dynamic group of registered dietitians all with the same mindset of improving the available resources for professionals and patients.

SAMPLE
Not for Print
Or Sale

Contributors

Sarita Bajpai, PhD, RDN, CD, CNSC

Clinical Dietitian Specialist, IU Health
Indianapolis, IN

Christine Benedetti, MS, RDN, CSR, LD, FNKF

Clinical Dietitian, Children's HealthScare of Atlanta
Atlanta, GA

Judith Beto, PhD, RDN, FAND

Research Associate, Loyola University Healthcare
Maywood, IL

Deborah Brommage, MS, RDN, LDN

Senior Scientific Director, National Kidney Foundation
Boynton Beach, FL

Joan Brookhyser Hogan, RD, CD

Registered Dietitian, Food 4 Life Nutrition Counseling
Tacoma, WA

Michelle Bump, MS, RD, LD

Director, Didactic Program in Dietetics;
Clinical Coordinator, Dietetic Internship,
Oregon State University
Corvallis, OR

Jenni Carvalho -Salemi, MPH, RDN, LD, CSP

Director, SAGE Research Group
Lutz, FL

Carolyn C. Cochran, RDN, LD, MS, CDCES, FNKF

Senior Clinical Dietitian, Dallas Nephrology
Associates, Dallas Transplant Institute
Dallas, TX

Sara Colman Carlson, RDN, CDCES

Manager, DaVita, Inc
Huntington Beach, CA

Rebecca Chrasta, MCN, RDN, LD

Registered Dietitian, Parkland Health
Dallas, TX

Joanne Cooke, MS, RD, CSR, FAND

Advanced Practice Renal Dietitian,
Kansas City VA Medical Center
Kansas City, MI

Ann Beemer Cotton, MS, RD, CNSC

Clinical Dietitian Specialist in Critical Care,
IU Health, Methodist Hospital
Indianapolis, IN

Desiree de Waal, MS, RD, CD, FAND

Renal Dietitian, University of Vermont Medical Center
Burlington, VT

Marian Glick-Bauer, MS, RD, CDN, CSR, CNSC

Clinical Dietitian, North Shore University Hospital,
Northwell Health
Manhasset, NY

Donna E. Gjesvold, RDN, LD, CCTD

Clinical Dietitian, Hennepin Healthcare, Kidney Center
Minneapolis, MN

D. Jodi Goldstein-Fuchs, DSc, CNN-NP, NP-C, RD

Nephrology Nurse Practitioner, Lucille Packard
Children's Hospital, Stanford, Pediatric Nephrology
Palo Alto, CA

Janelle E. Gonyea, RDN, LD, FNKF

Clinical Dietitian
Rochester, MN

Haewook Han, PhD, RD, LDN, FNKF

Department of Nephrology, Atrius Health;
Director of Combined MS in Nutrition & Dietetic
Internship, Friedman School of Nutrition
Science and Policy, Tufts University
Boston, MA

Peggy Hipskind, MA, RD, LD

Advanced Practice II Clinical Dietitian, Cleveland Clinic
Cleveland, OH

Wai Yin Ho, MEd, MS, RDN, LD

Learning Experience Designer
Charleston, SC

Kathleen Hunt, RD, CSR

Renal Dietitian, Kaiser Permanente
Hayward, CA

Pamela S. Kent, MS, RD, CDCES, LD

Director of Population Health-Ohio Somatus
Vermilion, OH

Judith Kirk, MS, RDN, CDN, CSR, FNKF

Clinical Nutrition Specialist, Solid Organ Transplant
Dietitian, University of Rochester Medical Center
Rochester, NY

Meredith Larsen, MS, RDN, LD, FNKF

Program Manager, Nutritional Services, DaVita Inc
Cedar Park, TX

Kristin Leonberg, MS, RD, CSR, CDCES

Global Scientific Communications, Rare Disease
Cambridge, MA

Rachael R. Majorowicz, RDN, CSR, LDN, FNKF

Renal Dietitian, Mayo Clinic
Rochester, MN

Heidi Mathes, RD, LD, CNSC

Clinical Dietitian Specialist, Mercy One West
Des Moines Medical Center
West Des Moines, IA

Lesley McPhatter, MS, RDN, CSR

Assistant Clinical Nutrition Manager, Renal Nutrition,
University of Virginia/Morrison Healthcare
Lynchburg, VA

Eileen Moore, RD, LD

Clinical Liaison Director, Renal Products,
Pentec Health Inc
Glen Mills, PA

Aida L. Moreno-Brown, MS, RD, LD

Nutrition Manager, Fresenius Medical Care, University
of Texas at El Paso; El Paso Community College
El Paso, TX

Walter P. Mutter, MD

Chief of Nephrology, Newton-Wellesley Hospital
Newton, MA

Samer Nasser, MS

Nephrologist, Harvard Vanguard Medical Associates,
Beth Israel Deaconess Medical Center
Boston, MA

Hannah Norris, RDN, CSR

Transplant Dietitian, Banner University Medical Center,
Phoenix, Transplant Institute
Phoenix, AZ

Jessie M. Pavlinac, MS, RDN-AP, CSR, LD, FNKF, FAND

Adjunct Instructor, Oregon Health & Science University;
Adjunct Instructor, Rutgers University;
Adjunct Instructor, Oregon State University
Corvallis, OR

Sara Prato, MS, RDN

Dietitian, Puget Sound Kidney Centers
Mountlake Terrace, WA

Melissa Prest, DCN, MS, RDN, CSR, LDN

Foundation Dietitian,
National Kidney Foundation of Illinois
Chicago, IL

Mary Rath, MEd, RD, LD, CNSC

Nutrition Support Dietitian, Cleveland Clinic
Cleveland, OH

Sharon R. Schatz, MS, RD, CSR, CDCES

Retired Renal Dietitian III,
DaVita Kidney Care Home Program
Cherry Hill, NJ

Kathy Schiro Harvey, MS, RDN, CSR

Director of Nutrition Services,
Puget Sound Kidney Centers
Mountlake Terrace, WA

Elizabeth C. Shanaman, RDN, CD, FNKF

Manager of Nutrition and Fitness Services,
Northwest Kidney Centers
Seattle, WA

Brittany Sparks, RDN, CSR

Private Practice Renal Dietitian, Nutrition by
Brittany, LLC
Denver, CO

Jean Stover, RD, LDN

Renal Dietitian, DaVita Kidney Care
Philadelphia, PA

Gail Torres, MS, RD, RN

Senior Clinical Communications Director,
National Kidney Foundation
New York, NY

Karen Wiesen, MS, RDN, LDN, FNKF

Renal Dietitian/Inpatient Dietitian Supervisor,
Geisinger Medical Center
Danville, PA

Victor Yu, PhD, RD, BC-ADM

Renal Dietitian and Professor of Nutrition,
Fresenius Kidney Care and Georgia Military College
North Augusta, SC

Lindsay Zirker, MS, RD, CSR

Renal Dietitian and Consultant,
The Kidney RD, RenAlign
Ammon, ID

Reviewers

Dominique Adair, MS, RD

Clinical Director, Cricket Health
New York, NY

Lubna Akbany, RD, CSR

Consulting Renal Dietitian
Newport Beach, CA

Vishal Bagchi, MBA, RD, LD

Dialysis Consultant, Nutricia/Danone North America
Dallas, TX

Deborah Benner, MA, RD, CSR

Vice President, Clinical Support, DaVita Inc
Yorba Linda, CA

Melanie Betz, MS, RD, CSR, CSG, LDN

Chronic Kidney Disease Nutrition and Education
Specialist, University of Chicago Medicine
Chicago, IL

Gloria M. Bissler, RD, LD

Renal Dietitian, Dialysis Clinic, Inc
Cincinnati, OH

Krista Blackwell, MD, RD, LDN, CNSC

Dietitian II, Sodexo
Silver Spring, MD

Amy Clatanoff Brown, RD, CSR, LDN

Renal Dietitian, Fresenius Kidney Care
Yarmouthport, MA

Cathleen Burns, DCN, RDN, LDN

Nutrition Consultant
Acushnet, MA

Laura D. Byham-Gray, PhD, RDN, FNKF

Professor and Vice Chair of Research,
Rutgers University
Newark, NJ

Greg Cannon, MS, RD, LD/N

Renal Dietitian, Fresenius Kidney Care
Melbourne, FL

Winnie Chan, PhD, RD, FNKF

Postdoctoral Research Fellow,
University of Birmingham
Birmingham, United Kingdom

Jan C. Beyer, MS, RD, LDN, CNSC

Clinical Dietitian, Centennial Medical Center—
Tristar Division
Nashville, TN

Claudia D'Alessandro, BSc, RDN

Renal Dietitian Nutritionist, University of Pisa
Pisa, Italy

Desiree de Waal, MS, RD, CD, FAND

Renal Dietitian, University of Vermont Medical Center
Burlington, VT

Doris Delgado, RDN

Nutrition Therapy Consultant, Patient Care American
Los Angeles, CA

Toni DeVane, MS, RDN, CSR, LDN, CNSC

Lead Renal Clinical Case Manager, Pentec Health
Glen Mills, PA

April Diederich, RDN, CSR

Assistant Director, Marilyn Magaram Center,
California State University, Northridge
Northridge, CA

Andrea Dombrowski, MS, RD, LD

Renal Dietitian, Satellite Healthcare
Austin, TX

Tiffany Donahue, RD, CSR, LDN

Clinical Dietitian Specialist,
Hospital of the University of Pennsylvania
Philadelphia, PA

Julie Driscoll, RDN, CSG, CSR

Assistant Health Services Administrator,
Federal Bureau of Prisons
Ayer, MA

Sara Erickson, RD, CSR, LDN

Clinical Nutrition Supervisor,
Atrium Health Levine Children's Hospital
Charlotte, NC

Bonnie K. Everett, MS, RD, CSR, LD

Renal Dietitian, Fresenius Kidney Care
Canton, MI

Kathleen M. Hill Gallant, PhD, RD

Associate Professor, University of Minnesota
St Paul, MN

Patricia Mae Garcia, MS, RD

Registered Dietitian, San Ysidro Health PACE,
Fresenius Kidney Care
Chula Vista, CA

Sarvnaz Medarresi Gharami, MS, RD, LDN

Nutrition Manager, Fresenius Medical Care
Roxbury, MA

Marian Glick-Bauer, MS, BD, CDN, CSR, CNSC

Clinical Dietitian, North Shore University Hospital,
Northwell Health
Manhasset, NY

Vida Goudarzi, MS, RDN, CSR

Satellite Healthcare
San Jose, CA

Lisa Gutekunst, MEd, RD, CSR, CDN, FNKF

Dietitian, US Renalcare Research
Buffalo, NY

Heidi J. Haas, MS, RD, LD

Renal Dietitian, Grand River Medical Group—
Tri-State Dialysis
Dubuque, IA

Ana Maria Hernandez-Rosa, MS, RDN, LDN

Renal Dietitian, Fresenius Kidney
Care/American Renal Associates
Tampa, FL

Lois Hill, MS, RDN, LD, LDE, FAND

Owner, Nutrition Solutions
Lexington, KY

Dorothy C. Humm, MBA, RDN, CDN

Founder, The Preferred Nutritionist Organization
Brockport, NY

Ruth Kander, BSc (Hons), RD, MBDA, AFHEA

Renal Specialist Dietitian, Imperial College
Healthcare NHS Trust
London, United Kingdom

Jennifer Kernc, RD, CSR, LD, FAND

Vice President Market Development, InterWell Health
Waltham, MA

Jillian Klein, MS, RD

Clinical Dietitian, Trinity Health Muskegon
Muskegon, MI

Laura Koch, MS, RD, LMNT

Renal Dietitian, Dialysis Center of Lincoln, Inc
Lincoln, NE

Constance A. Laux, MEd, RDN, LD

Renal Dietitian, Davita Fort Wayne South
Fort Wayne, IN

Helen Lui, MS, RD

Renal Dietitian, Fresenius Kidney Care
Methuen, MA

Christiane L. Meireles, PhD, RD

Clinical Assistant Professor, University of Texas Health
Science Center, School of Nursing
San Antonio, TX

Diane L. Mettler, RD, CSR

Clinical Dietitian, The University of Colorado Hospital
Aurora, CO

Lynn Munson, MS, RD, LD

Renal Dietitian, Kidney Specialists of Minnesota
Brooklyn Center, MN

Margaret Murphy, PhD, RD, LD, FAND

Assistant Professor/Pediatric Renal Dietitian,
University of Kentucky Healthcare
Lexington, KY

Marjorie A. Naples, RD, CDN

Renal Dietitian, American Renal Associates,
Dialysis Center of Oneida
Oneida, NY

Christina L. Nelms, MS, RDN, LMNT

Pediatric Renal Nutrition Educator and Consultant,
PedsFeeds, LLC and University of Nebraska
Kearney, NE

Amy Myrtue Nelson, MPH, RD, CSR, CD

Renal Dietitian, Fresenius Kidney Care
Olympia, WA

Helen M. O'Connor, MS, RDN

Research Dietitian, Mayo Clinic
Rochester, MN

Laura Olejnik, MS, RD, LDN, CNSC

Renal Specialist, Akebia Therapeutics
Cambridge, MA

Joni Pagenkemper, MS, RD/LMNT, CDCES

Certified Diabetes Care and Education Specialist
Lincoln, NE

Chhaya Patel, MA, RDN

Sr, Program Manager Clinical Services,
ORCA Divisional Lead RD, Davita
Walnut Creek, CA

Jessica Prohn, MS, RD, CSR, LDN

Renal Dietitian, Cricket Health
Cambridge, MA

Megan Reynolds, MS, RD, CSR, LD

HEALTHY HELPiNGs Nutrition Services
Westlake, OH

Cate Rhodes, MS, RDN, LDN, CNSC

Clinical Dietitian III, Cone Health
Greensboro, NC

AnnaMarie Rodriguez, RDN, LD, FAND

Dietitian/Nutrition Consultant, Nutrition Directions LLC
Sturtevant, WI

Rebecca Schaffer, MS, RDN, LD

Clinical Dietitian, Mayo Clinic
Rochester, MN

Noelle Schleder, MS, RDN

Nutrition Coach, Stronger U Nutrition
Traverse City, MI

Natalie Sexton, MS, RDN, CSR, LD

Registered Dietitian, DaVita
Gilmer, TX

Susanna Slukhinsky, RD, CSR, CDN

Clinical Dietitian, Susanna Slukhinsky Nutrition
Brooklyn, NY

Sue Steiner, RD, LMNT, CSR, CDCES

Renal Dietitian, Dialysis Clinics Inc
Bellevue, NE

Cynthia J. Terrill, RDN, CSR, CD

Pediatric Renal Dietitian,
University of Utah School of Medicine
Salt Lake City, UT

Maria Tointon, RDN, CSR

Renal Dietitian, U.S. Renal Care
Honolulu, HI

Jessica D. Tower, MS, RD, CSR, LD, CCTD

Clinical Nutrition Specialist III, Children's Mercy Hospital
Kansas City, MO

Dana Trotta, MS, RD, CSR, LDN, FNKF

Renal Dietitian, American Renal Associates
Narragansett, RI

Girija Vijaykumar, RD

Renal Dietitian, Pure Life Renal
Lansdowne, VA

Jennifer Vyduna, MS, RDN, CNSC

Lead Renal Clinical Case Manager, Pentec Health
Glen Mills, PA

Joanne L. White, RDN, LDN, CSR

Registered Dietitian Nutritionist Consultant
Wilmington, NC

Gretchen Wiese, MS, RDN

Associate Dietitian, Fresenius Kidney Care
Indianapolis, IN

Karen Wiesen, MS, RDN, LDN, FNKF

Inpatient Dietitian Supervisor and Renal Dietitian,
Geisinger Medical Center
Danville, PA

Melissa Young, MS, RDN, CSR, LDN

VA Dietitian
Asheville, NC

Lindsay Zirker, MS, RD, CSR

Renal Dietitian and Consultant, The Kidney RD, RenAlign
Ammon, ID

Preface

Nearly four decades ago, the Renal Dietitians Dietetic Practice Group of the Academy of Nutrition and Dietetics and the Council on Renal Nutrition of the National Kidney Foundation began development of a clinical guide to assist dietetic professionals managing the nutrition care of persons with kidney disease. At that time, renal dietitians were surveyed and they identified three key objectives for the publication. The *Clinical Guide to Nutrition Care in Kidney Disease* should address the following objectives:

1. Contain practical information that is useful in day-to-day clinical practice.
2. Represent a consensus formed by clinical practitioners based on current scientific literature and experience.
3. Focus on characteristics unique to the kidney disease population.

This edition, as well as previous editions, was written with these key objectives in mind.

The *Clinical Guide to Nutrition Care in Kidney Disease* also recognizes that registered dietitian nutritionists (RDNs) who practice in the realm of nephrology nutrition provide both preventive and therapeutic nutrition care for individuals of all ages who present with a variety of kidney disorders, requiring a continuum of treatment options to successfully manage established kidney disease. Consequently, this third edition of *Clinical Guide to Nutrition Care in Kidney Disease* continues to expand content to keep pace with the rapidly evolving field of nephrology. Enduring content areas have been updated to reflect the newly published Kidney Disease Outcomes Quality Initiative (KDOQI) Clinical Practice Guideline for Nutrition in CKD: 2020 Update. Updates also support the efforts of practitioners to achieve goals set forth by the July 2019 Executive Order on Advancing American Kidney Health which focuses on the prevention of progressive chronic kidney disease (CKD) and the promotion of home dialysis modalities as well as kidney transplantation in the event that CKD progresses to the point where kidney replacement therapy is required, ultimately improving medical care and quality of life for individuals with kidney disease.

The number of topics have been expanded to reflect the ever-broadening scope of practice for RDNs employed in outpatient clinics, transplant centers, dialysis facilities, long-term care facilities, and hospitals. New topics found in the third edition include nutritional management of kidney stones, guidelines for patients following plant-based diets to support recommended dietary patterns in the 2020 KDOQI update, CKD and gut health, information regarding herbal and botanical use in patients with transplant as well as malnutrition criteria, nutrition focused physical examination, and an overview of oral nutrition supplements for use in patients with kidney disease to help prevent or treat malnutrition that is commonly identified in this patient population.

This third edition of the *Clinical Guide to Nutrition Care in Kidney Disease* will provide continuing education credits for those who desire to pursue this option and assist RDNs who are preparing to take the credentialing examination to become a Certified Board Specialist in Renal Nutrition. With the aforementioned enhancements, we hope that you will find this third edition of the *Clinical Guide to Nutrition Care in Kidney Disease* to be an invaluable resource as you care for individuals with kidney disease.

A special thank you to previous clinical guide coeditors Karen Wiesen, MS, RDN, LDN, FNKF, Jean Stover, RD, LDN, and Laura Byham-Gray, PhD, RDN, FNKF, for their guidance and support with the third edition.

Acknowledgements

We would like to acknowledge a number of individuals, as without their support, publication of the third edition of this clinical guide would not have been possible. First, we would like to thank the previous coeditors of the clinical guide, Laura Byham-Gray, PhD, RDN, FNKF; Jean Stover, RD, LDN; and Karen Wiesen, MS, RDN, LDN, FNKF. Not only have they provided us with the first and second edition of this publication, but each was more than happy to help answer questions as we navigated through the publication process. Next, we would also like to thank the Academy of Nutrition and Dietetics Product Strategy and Development team including Betsy Hornick, MS, RDN, Emily Motycka, Erin Fagan Faley, and Stacey Zettle, MS, RDN, LDN. Each provided invaluable support and encouragement from the beginning to the end of this project. Lastly, thank you to all of our authors and reviewers for volunteering your time and expertise to write and provide feedback on this next edition. The field of nephrology nutrition continues to evolve, and with your support the *Clinical Guide to Nutrition Care in Kidney Disease* remains a great resource for registered dietitian nutritionists.

SECTION I

Overview of Kidney Disease and Nutrition Assessment



CHAPTER 1

Overview: Pathophysiology of the Kidney

Janelle E. Gonyea, RDN, LD, FNKF, and Brittany Sparks, RDN, CSR

Basic Kidney Anatomy

The kidneys are located symmetrically on either side of the vertebrae, starting at the 12th thoracic vertebra and extending down to the third lumbar vertebra. Each adult kidney measures approximately 11 cm to 12 cm long, 5 cm to 7.5 cm wide, 2.5 cm to 3 cm thick, and weighs approximately 115 g to 170 g. Each kidney has two general regions: the cortex, and the medulla (see Figure 1.1). The medulla is divided into cone-shaped regions called renal pyramids.¹ Blood is supplied to healthy kidneys through the renal artery, which enters the kidney at the hilus. Approximately 20% of cardiac output circulates to the kidneys. This is far more blood

flow than necessary to supply needed oxygen to the kidneys, but it is required for excretory function.² Urine that has been formed collects in the lower portion of the renal pelvis, which is the expanded upper region of the ureter. It then exits the kidney via the ureter that extends for a length of 22 cm to 30 cm, providing a connection to the bladder.³

The basic functional unit of the kidney is the nephron (see Figure 1.2 on page 2). On average, each human kidney contains 900,000 to 1 million nephrons, which are located in both the cortex and the medulla.⁴ Within each nephron, there are several well-known microscopic components (see Box 1.1 on page 2).

FIGURE 1.1 | Anatomy of a kidney





FIGURE 1.2 | Nephron



BOX 1.1 | Functional Units of the Nephron⁴

NEPHRON COMPONENT	FUNCTION
Glomerulus/ Bowman's capsule/ renal corpuscle	<p>Serves as the kidney's filtering unit</p> <p>Made of a network of capillaries surrounded by a narrow wall of epithelial cells</p> <p>Forms approximately 125 mL/min of filtrate within the glomerulus</p> <p>Bowman's capsule, with its basement membrane, encompasses the glomerulus (Together they are known as the renal corpuscle)</p>
Proximal convoluted tubule	<p>Is a direct continuation of the epithelium of the Bowman's capsule</p> <p>Controls reabsorption of filtered glucose, amino acids, sodium, bicarbonate, potassium, chloride, calcium, phosphate, water, and other solutes</p> <p>Manages secretion of renally excreted drug metabolites</p> <p>Produces ammonium</p>
Loop of Henle	<p>Concentrates urine which may be diluted later in the excretory system</p> <p>Unable to permeate water—but sodium can be pumped out</p> <p>Influences movement of water in or out of the water-permeable collecting duct</p>
Distal tubule	<p>Comprised of three parts:</p> <ol style="list-style-type: none"> 1. the thick ascending limb of the loop of Henle 2. the macula densa 3. the distal convoluted tubule <p>Has ability for active transport of sodium chloride in the thick ascending limb of the loop of Henle</p> <p>Concentrates urine by absorbing approximately 99% of the water that is filtered by the kidneys back into the body</p> <p>Thick ascending limb of loop of Henle functions are governed by hormones, including vasopressin, parathyroid hormone, and calcitonin</p>
Collecting duct	<p>Contains two types of cells: principal cells and intercalated cells</p> <p>Controls reabsorption of sodium chloride and the secretion of potassium via principal cells</p> <p>Regulates acid-base balance via secretion of hydrogen and bicarbonate in intercalated cells</p>

Kidney Functions

The major functions of the kidneys can be described as excretory, acid-base balance, endocrine, and fluid and electrolyte balance.

Excretory functions of the kidneys include removing excess fluid and waste products. While approximately 180 L of filtrate pass daily through the kidneys, only 1 to 2 L are removed in the urine each day.⁵ The remaining fluid is retained in the body to support tissues. Substances removed with the urine include urea, vitamins and minerals consumed in excess of the body's requirements, and metabolites of some drugs and poisons. If the blood levels of any needed substances are low, the kidneys promote homeostasis by conserving them to maintain levels within narrowly defined limits.

Acid-base balance is maintained through a buffer system, which keeps the blood's pH level at approximately 7.4. Bicarbonate carries hydrogen ions to the kidney, where they are removed from extracellular fluid in the tubules, then reabsorbed in the proximal tubule, and then returned as needed to the bloodstream. In addition, phosphate buffers intracellular fluid, which is concentrated in the tubules as water is removed. Other organic compounds, such as citrate, also support acid-base balance. Finally, metabolites of amino acids may be used to moderate acid or base reactions.⁶

Several hormones are included in the endocrine function of the kidneys. Calcitriol, or 1,25-dihydroxy-vitamin D₃, is produced in the kidney and subsequently enhances calcium absorption. In healthy kidneys, the activation of vitamin D and the excretion of excess phosphorus set the stage for maintaining healthy bones (see Chapter 10 for more details).

Anemia of patients with chronic kidney disease (CKD) is related to altered production of erythropoietin (EPO) in the diseased kidney. Normally, EPO acts on bone marrow to increase the production of red blood cells, thus enhancing the transportation of oxygen throughout the body's tissues. In patients with CKD, decreased production of EPO can lead to anemia (see Chapter 2 for more details).

The kidneys play an important role in maintaining fluid and electrolyte balance. Antidiuretic hormone (ADH), also known as arginine vasopressin, is released from the posterior pituitary gland and helps regulate water that is reabsorbed into the body. When fluid volume (blood or other fluids) is low, ADH is secreted and reduces urine flow, increasing the reabsorption of water in the collecting duct. This mechanism maintains the body's osmolality within a very tight range.

When extracellular volume decreases, the perfusion of all body tissues—including the kidney—is reduced. Consequently, the glomerular filtration rate (GFR) is lower, resulting in decreased removal of sodium chloride. This activates the trio of hormones of the renin-angiotensin-aldosterone system to increase blood pressure to maintain adequate tissue perfusion.⁷

A person with advanced kidney function impairment may experience edema, uremia (accumulation of waste products in the blood), metabolic acidosis, hypertension, anemia, bone disease, and increased sensitivity to certain medications, vitamins, minerals, and dietary supplements, which can reach toxic levels in the body.

Types of Kidney Failure

The onset of kidney failure can be sudden, as in acute kidney injury (AKI), or progressive, leading to CKD. Patients with AKI will potentially regain their kidney function with medical treatment of the underlying cause of insult. However, if a decrease in GFR or an increase in serum creatinine persists for more than 3 months after the diagnosis of AKI, the kidneys are not expected to recover, resulting in CKD. Typically, CKD cannot be reversed but may be stabilized with certain etiologies. Additional challenges for patients with significant proteinuria should also be addressed. Medical nutrition therapy (MNT) is important in both the management of AKI and CKD and will be discussed in detail in Chapters 3 and 4.

ACUTE KIDNEY INJURY

AKI generally has a rapid onset of symptoms occurring over a period of hours to days. AKI may start with a small increase in serum creatinine and progress to reduced urine volume (oliguria) and ultimately to a complete absence of urine output (anuria).⁸ AKI can occur in previously healthy kidneys. With proper nutrition management and appropriate dialytic support, ranging from intermittent hemodialysis to continuous venovenous hemodiafiltration, the kidneys can often repair themselves (see Chapter 4).⁹ However, AKI can often be superimposed on underlying CKD secondary to diabetes, hypertension, and other comorbidities. In this scenario, the goal is to return kidney function to baseline by removing the offending agent and avoiding chronic dialysis. AKI is associated with a high degree (40%–70%) of morbidity and mortality, despite advancing technology in kidney replacement therapy (KRT).^{10,11} AKI is also associated with increased risk for development of CKD, even when there is complete recovery of kidney function.¹⁰⁻¹³

In the United States, AKI most commonly occurs in hospitalized and critically ill patients and is often secondary to ischemic events and consequent injury to the kidney. However, AKI can arise from many different etiologies. AKI can be characterized by the type of underlying insult to the kidney and is categorized as either prerenal, intrinsic or tubulointerstitial, or postrenal.¹⁴⁻¹⁶ Prerenal AKI results from decreased kidney perfusion in an otherwise normal kidney, perhaps due to altered cardiac function and altered glomerular blood flow; with treatment, it can be quickly reversed. AKI may have a kidney origin due to underlying structural or functional changes in the kidney, and postrenal etiologies of AKI may include urethral strictures, tumors, clots, or stones restricting flow to or from the urinary tract.^{14,16} Identifying where the damage may be occurring within the kidney is key to treatment (see Chapter 4 for a more detailed discussion on AKI).

CHRONIC KIDNEY DISEASE

In 1997, the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-KDOQI) began publishing evidence-based clinical practice guidelines. These guidelines were developed and implemented by physicians and health care providers within the nephrology community. In 2002, NKF-KDOQI outlined a standard for classifying stages of CKD.¹⁷ A decade later, the Kidney Disease: Improving Global Outcomes (KDIGO) organization offered an update to the initial guidelines. The classification for CKD appears in Table 1.1.¹⁸

TABLE 1.1 | Stages of Chronic Kidney Disease¹⁸

Stage	Glomerular filtration rate (mL/min/1.73 m ²)	Description
G1	≥90	Kidney damage with normal or increased glomerular filtration rate (GFR)
G2	60-89	Mild decrease in GFR
G3a	45-59	Mild-to-moderate decrease in GFR
G3b	30-44	Moderate-to-severe decrease in GFR
G4	15-29	Severe decrease in GFR
G5	<15	Kidney failure

It is important to note that some decrease in kidney function is a normal part of aging. CKD stage 1 and even CKD stage 2 may be observed in otherwise healthy individuals aged 60 years and older. However, even in older adults, reduced kidney function should be monitored to allow appropriate intervention if the decrease in GFR continues into later stages of CKD.¹⁹

Patients with CKD continually lose GFR over a period of months to years. In many of the underlying conditions, progression of the disease continues even if the kidney is no longer exposed to the initial insult. Eventually, CKD may progress to stage 5, requiring KRT, such as dialysis or transplantation, to sustain life (see Chapters 5, 6, 7 and 8 for more details).

Nephrotic Syndrome

Nephrotic syndrome (NS) is one of the most serious challenges in clinical nephrology.²⁰ NS is not a disease but rather a collection of symptoms that may be recognized in patients with CKD of several different etiologies. Box 1.2 shows the clinical characteristics of NS.²¹ Nephrotic range proteinuria is a common characteristic of NS, which is classified as greater than 3 g urinary protein loss in a 24-hour time frame. With NS, fundamental alterations of the kidney's glomerular basement membrane allow persistent loss of large amounts of protein and other large molecules to pass into the urine. Normal urinary protein losses are approximately 150 mg/d.²² Conditions often associated with NS include diabetes mellitus, glomerular diseases, amyloidosis, minimal change disease, and focal segmental glomerulosclerosis (FSGS).²²

BOX 1.2 | Clinical Characteristics of Nephrotic Syndrome

Proteinuria (>3 g/d of urinary protein losses, with proportionally lesser amounts for children)

Hypoalbuminemia

Hypertension

Hyperlipidemia

Edema

A urinalysis is typically performed to determine the type and the amount of protein in the urine. This test helps to specify the kind of kidney damage that may be occurring and the necessary treatment. Low-molecular-weight protein losses are often associated with etiologies that affect the kidney tubules and often do not reach nephrotic range proteinuria.²²

“Albuminuria” is the term used to describe when albumin, a large-molecular-weight protein, is lost in the urine at levels higher than 30 mg/d. Albuminuria is classified as either moderately increased albuminuria with urine albumin levels between 30 mg/d and

300 g/d or severely increased albuminuria, when levels are more than 300 mg/d. These terms are now being used in place of microalbuminuria and macroalbuminuria.²² Albuminuria is considered to be problematic as it is associated with increased incidence of all-cause mortality, left ventricular hypertrophy, stroke, and vascular calcification.²² Albuminuria typically results from damage to the filtration barrier and can often be seen in patients with diabetes mellitus and NS.¹⁶

Since proteinuria, including albuminuria, represents such a high risk factor for cardiovascular disease and CKD progression, the treatment of NS must include reduction of urinary protein losses. Medical intervention may involve corticosteroids and immunosuppressive agents in several specific etiologies. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may also be used to reduce urinary protein losses and control blood pressure and fluid balance. The latter agents may be prescribed to reduce proteinuria even when blood pressure is normal.²¹

The etiology of hyperlipidemia in NS is related to excess production and reduced catabolism of apolipoprotein B–containing lipoproteins (including chylomicrons and very low-density lipoproteins). Some patients present with elevated levels of cholesterol and triglycerides.²³ Hyperlipidemia is associated with an increased risk for vascular disease and, therefore, hydroxymethylglutaryl coenzyme A reductase inhibitors are often used for lipid control. With some disorders, particularly FSGS, there may be a proteinuric factor, and the removal of this factor may help manage proteinuria and subsequent hyperlipidemia.²⁴

MNT for NS includes avoiding excessive protein intake, as large protein loads can exacerbate proteinuria. For those with CKD stage 1 and stage 2 with NS, a protein intake of 0.8 g/kg/d of body weight is recommended.^{25,26} Refer to Chapter 3 for more information on recommended protein needs for treating patients with CKD stages 3 through 5. Sodium restriction can be beneficial. One study recommends limiting sodium to 100 mmol/d or less than 2,300 mg/d in those with proteinuria; however, the overall goals should be

based on fluid status and the need to control edema.²⁷ Potassium, other electrolytes, and minerals need to be monitored, and the patient's diet should be individualized. Monitoring for vitamin D insufficiency and deficiency in patients with NS is important, as studies have shown increased risk due to increased loss of vitamin D-binding proteins in the urine.²⁷⁻³⁰ In patients with nephrotic range proteinuria, vitamin D supplementation with either cholecalciferol, ergocalciferol, or other safe and effective 25-hydroxyvitamin D precursors may be necessary to maintain adequate serum levels.²⁷ Nutrition therapy for the associated hyperlipidemia may not normalize serum cholesterol levels, and pharmacological therapy, as previously described, is generally required.^{25,26,30,31} More research and clinical trials are needed to identify optimal treatment for NS, especially for vitamin and mineral supplementation.

Summary

This chapter has provided an overview of normal kidney function and various consequences of kidney disease, along with many potential etiologies for compromise in kidney function including AKI, CKD, and NS. More detailed information regarding medical treatment and MNT required at these various stages will be found throughout this publication.

References

1. Fenton RA, Praetorius J. Anatomy of the kidney. In: Skorecki K, Chertow GM, Marsden PA, Taal MW, Yu ASL, eds. *Brenner and Rector's The Kidney*. 10th ed. Elsevier; 2016:42.
2. Munger KA, Maddox DA, Brenner BM, Kost CK Jr. The renal circulations and glomerular ultrafiltration. In: Skorecki K, Chertow GM, Marsden PA, Taal MW, Yu ASL, eds. *Brenner and Rector's The Kidney*. 10th ed. Elsevier; 2016:83.
3. Elkoushy MA, Andonian S. Surgical, radiologic, and endoscopic anatomy of the kidney and ureter. In: Wein AJ, Kavoussi LR, Partin AW, Peters CA, eds. *Campbell-Walsh Urology*. 11th ed. Elsevier; 2016:974.
4. Fenton RA, Praetorius J. Anatomy of the kidney. In: Skorecki K, Chertow GM, Marsden PA, Taal MW, Yu ASL, eds. *Brenner and Rector's The Kidney*. 10th ed. Elsevier; 2016:45-75.
5. Koeppen BM, Stanton BA. Renal transport mechanisms: NaCl and water reabsorption along the *nephron*. In: *Renal Physiology*. 5th ed. Elsevier Mosby; 2013:45-46.
6. Koeppen BM, Stanton BA. Regulation of acid-base balance. In: *Renal Physiology*. 5th ed. Elsevier Mosby; 2013:131-152.
7. Koeppen BM, Stanton BA. Regulation of body fluid osmolality: regulation of water balance. In: *Renal Physiology*. 5th ed. Elsevier Mosby; 2013:75-82.
8. Levin A, Warnock DG, Mehta RL, et al. Acute Kidney Injury Network Working Group: improving outcomes from acute kidney injury: report of an initiative. *Am J Kidney Dis*. 2007;50(1):1-4. doi:10.1053/j.ajkd.2007.05.008
9. The VA/NIH Acute Renal Failure Trial Network. Intensity of renal support in critically ill patients with acute kidney injury. *N Engl J Med*. 2008;359(1):7-20. doi:10.1056/NEJMoa0802639
10. Palevsky PM, Liu KD, Brophy PD, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury. *Am J Kidney Dis*. 2013;61(5):649-672. doi:10.1053/j.ajkd.2013.02.349
11. Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. *JAMA*. 2005;294(7):813-818. doi:10.1001/jama.294.7.813
12. Heung M, Steffick DE, Zivin K, et al. Acute kidney injury recovery pattern and subsequent risk of CKD: an analysis of veterans health administration data. *Am J Kidney Dis*. 2016;67(5):742-752. doi:10.1053/j.ajkd.2015.10.019
13. Mehta S, Chauhan K, Patel A, et al. The prognostic importance of duration of AKI: a systematic review and meta-analysis. *BMC Nephrol*. 2018;19(1):91. doi:10.1186/s12882-018-0876-7
14. Himmelfarb J, Joannidis M, Molitoris B, et al. Evaluation and initial management of acute kidney injury. *Clin J Am Soc Nephrol*. 2008;3(4):962-967. doi:10.2215/CJN.04971107
15. Basile DP, Anderson MD, Sutton TA. Pathophysiology of acute kidney injury. *Compr Physiol*. 2012;2(2):1303-1353. doi:10.1002/cphy.c110041
16. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. *Kidney Int Suppl*. 2012;2(suppl 1):78-80. doi:10.1038/kisup.2012.1

17. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney Dis.* 2002;39(2 suppl 1):S1-S266.
18. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney Int.* 2013;3(1):5. doi:10.1038/kisup.2012.74
19. Glasscock RJ, Winearls C. Aging and the glomerular filtration rate: truths and consequences. *Trans Am Clin Climatol Assoc.* 2009;120:419-428.
20. Schwarz A. New aspects of the treatment of nephrotic syndrome. *J Am Soc Nephrol.* 2001;12(suppl 17):S44-S47.
21. Orth SR, Ritz E. Medical progress: the nephrotic syndrome. *N Engl J Med.* 1998;338:1202-1211. doi:10.1056/NEJM199804233381707
22. Gilbert SJ, Weiner DE, Bombback AS, Perazella MA, Tonelli M. *National Kidney Foundation's Primer on Kidney Diseases.* 7th ed. Elsevier; 2018:46-49.
23. Crew RJ, Radhakrishnan J, Appel G. Complications of the nephrotic syndrome and their treatment. *Clin Nephrol.* 2004;62(4):245-259. doi:10.3345/kjp.2011.54.8.322
24. Keane WF. Proteinuria: its clinical importance and role in progressive renal disease. *Am J Kidney Dis.* 2000;35(4 suppl 1):S97-S105. doi:10.1016/S0272-6386(00)70237-X
25. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. *Kidney Int Suppl.* 2021;2(suppl 2):S139-274. doi:10.1038/kisup.2012.9
26. Fouque D. Nephrotic syndrome and protein metabolism. *Nephrologie.* 1996;17(5):279-282.
27. National Kidney Foundation. K/DOQI Clinical Practice Guideline for Nutrition in Chronic Kidney Disease: 2020 Update. *Am J Kidney Dis.* 2020;76(3 suppl 1):S1-S107. doi:10.1053/j.ajkd.2020.05.006
28. Selewski DT, Chen A, Shatat IF, et al. Vitamin D in incident nephrotic syndrome: a Midwest Pediatric Nephrology Consortium study. *Pediatr Nephrol.* 2016;31(3):465-472. doi:10.1007/s00467-015-3236-x
29. Barragry JM, France MW, Carter ND, et al. Vitamin D metabolism in nephrotic syndrome. *Lancet.* 1977;2:629-32. doi:10.1016/s0140-6736(77)92498-9
30. Molfino A, Don BR, Kaysen GA. Nutritional and non-nutritional management of the nephrotic syndrome. In: Kopple JD, Massry SG, Kalantar-Zadeh K, eds. *Nutritional Management of Renal Disease.* 3rd ed. Elsevier; 2012:26.
31. Kaysen GA. Nutritional management of nephrotic syndrome. *J Ren Nutr.* 1992;2(2):50-58. doi:10.1016/S1051-2276(12)80212-3

Index

Page numbers followed by *b*, *f* and *t* refer to boxes, figures and tables, respectively.

- AADE7 self-care behaviors, 143–145, 143*f*
- abdominal fat deposition, 14
- abdominal obesity, 14–15
- abnormal mineral metabolism, 189, 226–228
- Academy of Nutrition and Dietetics Health Informatics Infrastructure (ANDHII), 463–464
- Academy of Nutrition and Dietetics Quality Management Committee, 456
- acarbose (Precose), 368*b*
- acebutolol (Sectral), 363*b*
- acid-base balance, 3
- acidemia, 67, 170
- acid-forming foods and protein, 302–303
- acid neutralizer, 381*b*
- acidosis, 153, 163, 333, 348
- acute disease- or injury-related malnutrition, 54
- acute hyperglycemia, 150–151
- acute kidney injury (AKI), 3–4, 139, 321, 339
 - causes of, 52*b*
 - critical illness, 55
 - daily energy and nutrient recommendations for, 59*b*
 - definition and classification, 49–50
 - diagnostic criteria for, 50*b*
 - etiology and pathology, 50–52
 - infusion and monitoring and parenteral nutrition, 340
 - intrinsic or tubulointerstitial causes, 51–52
 - kidney replacement therapy in, 53–54
 - laboratory assessment, 55–58
 - malnutrition and parenteral nutrition, 337–338
 - metabolic alterations associated with, 59*b*
 - nutrient requirements and components, 338–340
 - nutrition assessment, 54–55
 - nutrition needs/nutrition prescription, 58–60
 - nutrition support, 60–62
 - oral intake, 60
 - and parenteral nutrition, 337–340
 - physical assessment, 55
 - postrenal causes, 51
 - prerenal causes, 51
 - RIFLE criteria, 49*f*
 - staging for, 50*t*
- Acute Kidney Injury Network (AKIN), 50
- acute posttransplant period
 - immunosuppressive therapy, 114–118
 - nutritional requirements, 118–121
 - posttransplant nutrition concerns, 121–127
- acute stress, 19
- adenosine, 190
- adequate dialysis, 65–66, 91
- adherence, 207–208
- adipocyte, 22
- administration of enteral feedings, 322
 - delivery systems, 322
 - feeding schedules, 322–323
- adult incenter hemodialysis patient, nutrition management
 - anemia management and iron, 74
 - bone metabolism, 72–73
 - daily recommended nutrient intakes, 69*b*–70*b*
 - dialyzer, dialysis bath, and access, 65–67
 - energy, 71
 - geriatric nutrition needs on hemodialysis, 74–76
 - lipids, 71
 - potassium, 71–72
 - protein, 68
 - sodium and fluid, 71
 - vitamin properties, 75*t*
- adult kidney transplant patient
 - acute posttransplant period, 114–118
 - long-term posttransplant period, 127–131
 - nutritional requirements, 118–121
 - posttransplant nutrition concerns, 121–127
 - pretransplantation period, 112–114
- adult on dialysis, 456
- adult with pre-ESRD, 456
- advanced glycation end products (AGEs), 151
- Advancing American Kidney Health, 80
- adynamic bone disease, 192–193

- age-and gender-specific growth charts, 249
- age-appropriate dietary recommendations, 257
- AKI. *See* acute kidney injury (AKI)
- albumin, 19, 55
- albuminuria, 5, 38–39, 147
- alcohol abuse, 19
- aldosterone receptor antagonists, 72
- α -linolenic acid (ALA), 434
- alimentation, 340
- alkaline phosphatase, 189
- allopurinol (Zyloprim), 304, 374*b*
- aloe vera (*Aloe barbadensis*), 398–399
- altered mineral metabolism in CKD, 227
- aluminum carbonate, 202
- aluminum-containing antacids, 247
- aluminum hydroxide (Amphojel, AlternaGEL, Alucaps), 202, 377*b*
- American Association of Clinical Endocrinology (AACE), 128, 141
- American College of Endocrinology (ACE), 142–143
- American Diabetes Association (ADA), 39, 128, 140
- American Diabetes Association General Goals of Medical Nutrition Therapy, 158
- American diet, 39
- American Heart Association, 71
- American Society for Parenteral and Enteral Nutrition (ASPEN), 38, 54
- amiloride hydrochloride (Midamor), 362*b*
- amino acids, 330, 338, 344. *See also* intraperitoneal amino acids/intraperitoneal nutrition
- amiodarone (Nexterone), 362*b*
- amyloidosis, 5
- anabolic hormones, 67
- anemia, 3, 22–23, 130, 237, 359
 - long-term posttransplant period, 130
- anemia and chronic kidney disease, medication
 - erythropoietin-stimulating agents (ESAs), 360*b*
 - hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor, 361*b*
 - iron-based phosphate binder, 361*b*
 - iron preparations, 360*b*
- anemia management
 - hematological parameters and therapy, 23–25
 - pathophysiology, 22–23
- angiotensin blockers, 72
- angiotensin-converting enzyme (ACE) inhibitors, 5, 72, 148, 223, 237
- angiotensin potassium-sparing diuretics, 56–57
- angiotensin receptor blockers (ARBs), 5, 148, 223, 237
- anhydrous glucose, 90
- animal-based low-protein diet, 41
- animal-based protein, 431
- animal protein, 302
- annual urine testing, 146
- anorexia, 105, 317
- antacids, 337
- anthropometrics and physical exam
 - amputation adjustments, 13*t*
 - body mass index (BMI), 14
 - body weight (BW), 11–12, 12*t*–13*t*
 - conicity index (CI), 15
 - creatinine kinetics, 15
 - frame size, 14
 - height, 13–14
 - interdialytic weight gains, 12–13
 - skinfold thickness, 15
 - waist circumference, 14–15
- antibiotics, 105, 168, 203*t*, 269, 306, 403, 414, 443, 445*f*
- anticoagulation, 230
- antidiabetic agents, 150, 169
- antidiuretic hormone (ADH), 3
- antiemetics, 168
- antihistamines, 189
- antihypertensive medications, 71
- anti-oxidative nutrition in hypoalbuminemic dialysis patients (AIONID) trial, 387
- antirejection therapy, 114
- antithymocyte globulin (ATG), 118
- anuria, 4, 60
- anxiety disorders, 172–173
- aortic smooth muscle cells, 190
- apixaban (Eliquis), 361*b*
- appetite, 104–105
- arginine vasopressin, 3
- arm span, 13–14
- arterial calcification, 225
- arterial stiffening, 225
- arteriosclerosis, 224–225
- arteriovenous (AV)
 - access, 66
 - graft, 67
- artificial kidney, 65. *See also* kidney
- artificial sweeteners, 450
- ascorbic acid (vitamin C), 302, 397–398
- aspiration, 324*b*
- aspirin, 361*b*
- Association of Diabetes Care & Education Specialists (ADCES), 143
- asymptomatic hypocalcemia, 197
- atenolol (Tenormin), 363*b*
- atherosclerosis, 40, 168, 225

- atherosclerotic vascular disease, 51
 atorvastatin (Lipitor), 365*b*
 atrial fibrillation (AF), 223
 atrial natriuretic peptides, 22
 attitude, renal dietitian, 470–471
 automated peritoneal dialysis (APD), 87, 88*b*, 92*b*–93*b*
 autonomic nervous system dysfunction, 149
 autonomic neuropathy (AN), 153
 autosomal dominant hyperparathyroidism, 293
 azathioprine (Imuran), 115*b*, 117
 azotemia, 51
- bacterial contamination of feedings, 322
 bad cholesterol, 22. *See also* good cholesterol
 baneberry, 401–402
 bardoxolone, 380*b*
 bariatric surgery, 170–172
 basal calorie requirements, 127
 basiliximab (Simulect), 118
 beer, purine content, 305
 behavior-change skills, 471
 renal dietitian, 471
 bempedoic acid (Nexletol), 366*b*
 benazepril hydrochloride (Lotensin), 364*b*
 bendroflumethiazide (Aldactide, Naturetin), 362*b*
 Benefits Improvement and Protection Act (BIPA), 455
 benzothiazepine derivatives, 364*b*
 betamethasone (Celestone Soluspan, Sernivo), 379*b*
 betaxolol (Kerlone), 363*b*
 β -receptor blockers, 72
 bicarbonate, 3
 bicarbonate-lactate mixtures, 90
 Bifidobacteria, 444
 Bifidobacterium species, 443
 bioelectrical impedance analysis (BIA), 11, 250
 biotin, 42, 399–400
 bisacodyl (Dulcolax), 372*b*
 bismuth subsalicylate (bismuth), 374*b*
 bisoprolol fumerate (Zebeta), 363*b*
 bisphosphonates, 191
 black cohosh (*cimicifuga racemosa*), 401–402
 black snakeroot, 401–402
 blood flow rates (BFRs), 80–81
 blood glucose
 homeostasis, 149
 levels, fluctuation, 146
 blood pressure (BP)-lowering effects, 147
 blood urea nitrogen (BUN), 25, 51, 66, 83
- BMD. *See* bone mineral density (BMD)
 BMI. *See* body mass index (BMI)
 body mass index (BMI), 14, 34–35, 68, 232, 327
 body weight (BW), 11–12
 bone
 abnormalities, 194
 biopsy, 193
 disease, 3
 disease via biopsy, 192
 turnover, 187
 volume, 194
 bone mineral density (BMD), 168–169, 193
 bone-specific alkaline phosphatase, 194
 bowel ischemia, 61
 breastfeeding, 240–241
 Bristol Stool Form Scale, 207
 bug root, 401–402
 bumetanide (Bumex), 362*b*
 burn plant, 398–399
 burns, 19
- calcidiol, 187
 calcification, 225
 inducers, 190
 inhibitors, 190–191
 calcific uremic arteriopathy, 191
 calcimimetics, 84, 103–104, 191
 mineral and bone disorders and kidney disease, 211–212
 calciphylaxis, 191
 calcitriol (Calcijex, Rocaltrol), 3, 378*b*
 deficiency, 187
 production, 188*f*
 calcium, 81
 in acute kidney injury, 57
 adult peritoneal dialysis patient, 100
 in blood-clotting cascade, 21
 CKD-MBD, 20–21
 homeostasis, 20, 185, 301
 magnesium blends (Roloids), 376*b*
 mineral and bone disorders and kidney disease, 194–197,
 214
 mineral and hormonal abnormalities, 187
 supplements, 189
 calcium acetate (PhosLo–capsule or Phoslyra–liquid), 202,
 376*b*
 calcium-based antacids, 129
 calcium carbonate (Tums), 99, 202, 376*b*
 calcium-containing phosphate binders, 168, 191, 204
 calcium dialysate, 189

- calcium oxalate stones, 289
 - acid-ash and alkaline-ash foods, 303*b*
 - acid-forming foods and protein, 302–303
 - medical management, 299–300
 - nutritional management, 300–302
- calcium-phosphorus-PTH balance, 103–104
- calcium polycarboxophil (Equalactin, Fiber Tabs), 371*b*
- calcium-sensing receptors (CaSRs), 185, 227
- calcium stones
 - calcium oxalate stones, 289, 299–303
 - calcium phosphate stones, 303
 - crystal formation, 191
 - crystals, 189
- calorie load, 94
- canagliflozin (Invokana), 368*b*
- cancer, 52*b*, 130
 - bladder, 51
 - long-term posttransplant period, 130
- candesartan (Atacand), 364*b*
- CAPD. *See* continuous ambulatory peritoneal dialysis (CAPD)
- capsaicin, 165
- captopril (Capoten), 364*b*
- carbamylation of hemoglobin, 154
- carbohydrate, 338
 - absorption, determinant of, 160*f*
 - adult renal transplant patient, 118–119
 - consistency, 161
 - counting (carb counting), 160–161
 - management, dietary strategies for, 159–161
 - sparing dialysate solutions, 151
- carbonated beverages, 167
- carbonyl stress, 67
- cardiac diastolic dysfunction, 149
- cardiac dysfunction, 40
- cardiac mortality, 190
- cardiac muscle pathology, 225
- cardiac overload and acceleration, 150
- cardiac pathology, 224–225
- cardiovascular autonomic neuropathy, 166
- cardiovascular death, 71
- cardiovascular disease (CVD), 14, 39–41
 - abnormal mineral metabolism, 226–228
 - anticoagulation, 230
 - cardiac pathology, 224–225
 - congestive heart failure (CHF), 223
 - diabetes-related complications, comorbidities and concerns, 168
 - dyslipidemia, 225–226
 - homocysteinemia, 228–229
 - hypertension, 228
 - inflammation, 229
 - kidney transplant and cardiovascular disease, 229–230
 - prevalence, 224
 - registered dietitian nutritionist's role in, 230–233
 - risk factors, 223, 224*b*
- cardiovascular disease (CVD) and chronic kidney disease, medication
 - α -adrenergic agonists, 365*b*
 - angiotensin-converting enzyme (ACE) inhibitors, 364*b*
 - angiotensin II receptor blockers (ARBs), 364*b*
 - antiadrenergics, 363*b*
 - antiarrhythmics, 362*b*
 - antithrombotic agents, 361*b*
 - calcium channel blockers, 364*b*
 - cardiac glycosides (inotropic agents), 364*b*
 - combination medication used for heart failure, 365*b*
 - diuretics, 362*b*
 - dyslipidemia, 365*b*
 - vasodilators, 363*b*
 - vasopressin V2-receptor antagonist, 365*b*
- cardiovascular mortality, 232
- Cardiovascular risk Reduction by Early Anemia Treatment with Epoetin Beta (CREATE) trial, 231
- carotid and aortic stiffness, 225
- carteolol hydrochloride (Cartrol), 363*b*
- carvedilol (Coreg), 363*b*
- catabolic hormones, 67
- catch-up growth, 259
- catheter-related infections, 66
- CCPD. *See* continuous cyclical peritoneal dialysis (CCPD)
- Centers for Disease Control and Prevention, 14
- Centers for Medicare & Medicaid Services (CMS), 82, 456
- CfCs. *See* Conditions for Coverage (CfCs)
- CGM. *See* continuous glucose monitoring (CGM)
- chamomile (*Matricaria recutita*), 402–403
- change conversations, stages, 472*b*
- chemical-induced diabetes mellitus, 140
- chemotherapy, 61
- child's midparental, 248
- chlorothiazide (Diuril), 362*b*
- chlorpropamide (Diabinese), 367*b*
- chlorthalidone (Thalitone), 362*b*
- cholecalciferol, 6, 187
- cholestasis, 334
- cholesterol, 22
 - and low-density lipoprotein, 83
 - and triglycerides, adult peritoneal dialysis patient, 100–101
- cholestyramine (Questran, Prevalite), 168, 366*b*, 378

- chronic allograft nephropathy, 131
- chronic disease-related malnutrition, 54
- chronic hepatic problems, 19
- chronic illness, 10
- chronic inflammation, 141, 153
- Chronic Kidney Disease in Children study (CKiD), 249, 254
- chronic kidney disease (CKD), 4, 17*t*, 236–243, 317, 325, 396, 433
- as abnormalities, 33
 - anthropometrics and physical exam, 10–15
 - biochemical parameters, 16–26
 - calcimimetic agents, 378*b*
 - calcium-based binders, 376*b*
 - comorbidities of, 38–41
 - continuous quality improvement in, 458
 - daily recommended nutrient intakes for, 37*b*
 - diabetic kidney disease, 380*b*
 - energy and nutrient requirements, 16
 - estimating lean body mass in, 37*b*
 - inherited kidney diseases, 379*b*–380*b*
 - metabolic acidosis, 381*b*
 - mineral and bone disorder (CKD-MBD), 20–21
 - non-calcium-based phosphate binders, 376*b*
 - nutrition assessment tools, 26–27
 - patient history, 9–10
 - phosphate binders, 376*b*
 - and pregnancy, 236–243
 - pruritis, 381*b*
 - renal dietitian, 470
 - risk factors for, 33*b*
 - sodium/hydrogen exchanger 3(NHE3) inhibitor, 377*b*–378*b*
 - stages, 4*t*
- chronic kidney disease (CKD) and AN, 327–329
- acid-base balance, 333–334
 - administration, 335
 - amino acids, 330
 - components, 329–335
 - dextrose, 330–331
 - fluid, electrolytes, and minerals, 332–333
 - levocarnitine, 334–335
 - lipids, 331–332
 - monitoring patients, 335–337
 - nutritional care and intervention, 343*f*
 - peripheral parenteral nutrition, 337
 - vitamins and trace elements, 334
- chronic metabolic acidosis, 191–192
- Chronic Renal Insufficiency Cohort (CRIC) study, 189
- cimetidine (Tagamet), 370*b*
- cinacalcet HCl (Sensipar), 84, 378*b*
- cinnamon (*Cinnamomum verum*), 403–404
- circulatory toxic metabolites, 104
- CKD-EPI (CKD-epidemiology collaboration) Creatinine 2021 Equation, 18
- CKD-EPI Creatinine-Cystatin 2012 Equation, 18
- CKD stages 1 through 5, nutrition management
- cardiovascular disease, 39–41
 - diabetes, 38–39
 - energy requirements, 36–37
 - kidney healthy plate, 43*b*, 43*f*
 - malnutrition, 34–35
 - micronutrients and supplements, 41–42, 42*t*
 - protein requirements, 35–36
 - quantity vs quality, protein, 34
 - risk factors, 33*b*
 - self-management behavior and medical nutrition therapy, 42–44
 - in underweight and obese conditions, 37–38
 - vitamin supplementation recommendations, 42*t*
- clofibrate (Atromid-S), 366*b*
- clonidine hydrochloride (Catapres), 363*b*
- clopidogrel (Plavix), 361*b*
- Clostridium perfringens, 444
- cobalamin (vitamin B12), 42, 404–405
- coenzyme Q10, 405–406
- cognitive behavior therapy (CBT), renal dietitian, 472–473, 473*b*
- cognitive decline, hypoglycemia, 153
- colchicine (Colcrys), 374*b*
- colesevelam (Welchol), 366*b*
- colestipol (Colestid), 366*b*
- commercial amino acid, 347
- commercial beverages, 201
- Commission on Dietetic Registration, 457–458
- complementary and alternative medicine (CAM) therapies, 396
- concentration gradient, 65–66
- Conditions for Coverage (CfCs), 464–465
- congestive heart failure (CHF), 168, 223, 406
- conicity index (CI), 15
- constipation, 167, 324*b*, 433
- cause, 323
 - medications to treat, 371*b*–373*b*
- continuous ambulatory peritoneal dialysis (CAPD), 88, 92*b*–93*b*, 151, 208, 258, 330
- continuous arteriovenous hemodialysis (CAVHD), 53
- continuous arteriovenous hemofiltration (CAVH), 53
- continuous AV hemodiafiltration (CAVHDF), 53
- continuous cyclical peritoneal dialysis (CCPD), 88, 88*b*, 258

- continuous glucose monitoring (CGM), 156
- continuous quality improvement (CQI), 458–460
 - changing clinical practice, 459
 - monitor and evaluate, 459
 - planning, 459
 - quality cycle check, 459
- continuous renal replacement therapy (CRRT), 53, 58, 321
 - in hemodynamic instability patients, 60
- continuous venovenous hemodiafiltration (CVVHDF), 53
- continuous venovenous hemodialysis (CVVHD), 53
- continuous venovenous hemofiltration (CVVH), 53, 338
- coronary and peripheral artery calcifications, 168
- coronary artery calcification (CAC), 189
- coronary artery disease (CAD), 148
- coronary heart disease (CHD), 297
- Coronavirus Preparedness and Response Supplemental Appropriations Act, 458
- corticosteroids, 5, 115*b*, 117–118, 191
- Council on Renal Nutrition of the National Kidney Foundation, 475
- counseling considerations, 163–164
- C-reactive protein, 58
- creatinine kinetics, 15
- crystallization inhibitors, 290
- CVD. *See* cardiovascular disease (CVD)
- cyclic intermittent peritoneal dialysis, 258
- cyclosporine A (CsA), 114, 115*b*
- cystine stones
 - medical management, 305
 - nutritional management, 305–306
- cystinuria, 289, 293, 305
- cytokines and hormones, 247
- cytomegalovirus (CMV), 152
- dabigatran (Pradaxa), 361*b*
- daclizumab (Zenepax), 118
- dapagliflozin (Forxiga), 368*b*
- daprodustat, 361*b*
- Darbepoetin alfa (Aranesp), 360*b*
- DASH diet, 38
- dehydration, 324*b*, 325
- delayed gastric emptying, 247
- demi-span, 14
- denosumab (Prolia), 378*b*
- Dent's disease, 293
- depression, 172–173
- dexamethasone (Ozurdex), 379*b*
- dextrose, 330–331, 344
- dextrose monohydrate, 90
- diabetes epidemic, 140
- diabetes, 323, 399. *See also* specific entries
 - nutrition management in CKD stages 1 through 5, 38–39
 - peritoneal dialysis, adult patient on, 103
- diabetes and chronic kidney disease, medication
 - biguanides, 367 *b*
 - dipeptidyl peptidase (DPP)-4 inhibitors, 368*b*
 - glucagon-like peptide-1 receptor agonists, 369*b*
 - insulin, 369*b*
 - meglitinides, 367*b*
 - sodium-glucose cotransporter (SGLT)-2 inhibitors, 368*b*
 - sulfonylureas, 367*b*
 - thiazolidinediones (TZDs), 368*b*
 - α -Glucosidase inhibitors, 368*b*
- Diabetes Control and Complications Trial (DCCT), 145
- diabetes in chronic kidney disease
 - AADE7 self-care behaviors, 143–145
 - classifications and screening, 139–143
 - criteria for diagnosis of, 140*b*
 - diabetes-related complications, comorbidities, and concerns, 164–173
 - diabetic kidney disease and predialysis, 145–146
 - glucose-lowering medications, direct kidney effects, 146–147
 - glycemic control, 153–158
 - glycemic control and diabetic kidney disease, 146
 - hypertension management and diabetic kidney disease, 148–149
 - kidney disease and predialysis, 145–149
 - kidney replacement therapy, 149–152
 - medical nutrition therapy, 158–164
 - prediabetes and insulin resistance, 141–142
 - prediabetes or increased risk for developing, 140*b*
 - protein, energy, and diabetic kidney disease progression, 147–148
 - type 1 and type 2 diabetes, 142–143
- diabetes mellitus (DM), 5, 95, 399
 - distress, 173
 - ketoacidosis, 167
- diabetes-related complications, comorbidities and concerns
 - bariatric surgery, 170–172
 - cardiovascular disease, 168
 - diabetic neuropathy (DN), 164–168
 - diabetic retinopathy and visual problems, 164
 - fracture risk, 168–169
 - HIV, 170
 - malnutrition, 170
 - mineral and bone disorders, 168–169
 - obesity, 170–172

- oral health and dental disease, 169–170
- physical conditioning and exercise, 172
- psychological and mental health issues, 172–173
- diabetic acidosis, 19, 99
- diabetic diarrhea, 166
- diabetic enteropathy, 168
- diabetic foot disease, 165
- diabetic kidney disease (DKD), 139, 145–146
- diabetic neuropathy (DN), 139, 148, 165–168
 - autonomic neuropathy, 166–168
 - sensorimotor neuropathy, 165–166
- diabetic oral health complications, 169
- diabetic retinopathy and visual problems, 164
- dialysate, 67
 - bath, 65
 - calcium content, 239
 - concentrate composition, 81*t*
 - contents of, 66*b*
- dialysate flow rates (DFRs), 80–81
- dialysis
 - adequate, 65–66
 - adult on dialysis, 456
 - adult peritoneal dialysis patient, 95, 100
 - care education and intended outcomes, 81*b*
 - inadequate, 66
 - maintenance dialysis (MD), 257
 - mineral and bone disorders and kidney disease, 208–209
 - modality and treatment options, 79*b*
 - on-dialysis supplementation, 68
 - pediatric patient, kidney disease in, 258
 - peritoneal dialysis (PD), 11, 103, 150–152
 - post-dialysis BUN, 66
 - pregnancy, 237–239
 - prescription, 80–82
 - regimen, pregnancy, 237–239
 - stage 5 dialysis (CKD 5D), 87
 - sustained low-efficiency dialysis (SLED), 53
 - tidal peritoneal dialysis (TPD), 88, 88*b*, 258
 - transitional dialysis care, 80–81
 - vintage, 170
 - weight loss, 153
- dialysis adequacy, 25–26
 - blood urea nitrogen, 25
 - Kt/V, 25
 - urea reduction ratio (URR), 26
- dialysis-associated hyperglycemia, 150
- Dialysis Practice Patterns Outcomes Study (DOPPS) data, 10
- dialytic blood flow rate, 208
- dialyzer
 - fibers, 65
 - membranes, 65–66
- diarrhea, 323, 324*b*
- diastolic dysfunction, 168
- diet. *See also* dietary supplements; medical nutrition therapy; vegetarian, vegan, or plant-based diets
 - DASH diet, 38
 - gut microbiome, 448
 - home hemodialysis, adult patient on, 82–83
 - kidney stones, nutritional management, 307*b*
 - Western diet, 35–36
 - whole-diet approach, 159
- diet, adult patient on home hemodialysis, 82–83
- Dietary Approaches to Stop Hypertension (DASH), 301
 - diets, 34, 200, 231–232
- dietary fat, 162
- dietary fiber, 163
- dietary interviews, 10, 68
- dietary phosphate binding, 227
- dietary phosphorus, 41
 - restriction, 41
- dietary potassium restriction, 277
- dietary protein, 161–162
- dietary protein intakes (DPIs), 95
- Dietary Reference Intake (DRI), 42, 58
- dietary sodium restriction, 299
- Dietary Supplement Health and Education Act (DSHEA), 396
- dietary supplements, 396–397
 - aloe vera (*Aloe barbadensis*), burn plant, lily of the desert, elephant's gall, 398–399
 - ascorbic acid (vitamin C), 397–398
 - biotin (vitamin B7), 399–400
 - black cohosh (*cimicifuga racemosa*), Baneberry, black snakeroot, bug root, 401–402
 - chamomile (*Matricaria recutita*), 402–403
 - cinnamon (*Cinnamomum verum*), 403–404
 - cobalamin (vitamin B12), 404–405
 - coenzyme Q10, 405–406
 - echinacea (*Echinacea angustifolia* DC, *Echinacea pallida*, *Echinacea purpurea*), purple coneflower, 406–407
 - fish oil, omega-3 fatty acids, and α -linolenic acid, 408–410
 - flaxseed and flaxseed oil (*Linum usitatissimum*), 410–411
 - garlic (*Allium sativum*), 411–412
 - ginkgo (*Ginkgo biloba*), 412–414
 - ginseng, Korean ginseng or Asian ginseng (*Panax ginseng*), American ginseng (*Panax quinquefolius*), 414–415
 - glucosamine and chondroitin sulfate, 415–417

- green tea (*Camellia sinensis*), 417–418
 milk thistle (*Silybum marianum*), Lady's thistle, 418–419
 noni (*Morinda citrifolia*), 419–420
 retinol (vitamin A), 422–424
 saw palmetto (*Serenoa repens*), 420–421
 St John's wort (*Hypericum perforatum*), 421–422
 thiamin (vitamin B1), 424–425
- Dietetics Evidence Analysis Library (EAL), 147
 Dietetics House of Delegates, 456
 Dietetics Outcomes Registry, 463–464
 diet intervention, 72
 difelikefalin, 381*b*
 diffusion, 89
 digestive enzymes, 448*b*
 digestive issues, 444
 digital technology, 144
 digoxin (Digox, Lanoxin), 362*b*, 364*b*
 dihydropyridines, 364*b*
 1,25-dihydroxyvitamin D, 186–187
 1,25-dihydroxyvitamin D3, 3
 25-hydroxyvitamin D2, 187
 25-hydroxyvitamin D3, 187
 dioctyl calcium sulfosuccinate (Colace), 373*b*
 diphenoxylate hydrochloride/atropine sulfate (Lomotil), 168
 diphenylalkylamine derivatives, 364*b*
 Dish up a Kidney Friendly Meal, 161
 disopyramide phosphate (Norpace), 362*b*
 disordered physiology and progression of disease, 186–191
 calciophylaxis, 191
 cardiovascular disease, 189–191
 mineral and hormonal abnormalities, 187–189
 distal symmetric polyneuropathy (DSPN), 165
 diuresis, 55
 diuretic drugs, 399
 docosahexaenoic acid (DHA), 434
 docusate calcium (Colace, Correctol), 373*b*
 docusate sodium and dioctyl sodium sulfosuccinate (Docusate), 373*b*
 domperidone, 167
 double-cuff Tenckhoff, 90
 double-lumen tubes, 318
 doxazosin mesylate (Cardura), 363*b*
 doxercalciferol (Hectorol), 378*b*
 dronabinol (Marinol), 371*b*
 drug-drug interactions, 153, 168
 drug-nutrient interactions, adult renal transplant patient, 126–127
 drugs containing aluminum, 202
 dual-energy x-ray absorptiometry (DXA), 11, 36, 193, 250
 dulaglutide (Trulicity), 369*b*
 dysbiosis, 444
 in chronic kidney disease, 444–445
 and increased intestinal permeability, 447*b*
 resources for, 447*t*
 dyslipidemias, 22, 39–40, 225–226, 229, 345
 long-term posttransplant period, 128–129
 dysmetabolic syndrome, 141
 dysplastic kidneys, 237
- eating disorders, 172–173
 echinacea (*Echinacea angustifolia* DC, *Echinacea pallida*, *Echinacea purpurea*), purple coneflower, 406–407
 edema, 3, 6, 15, 55, 258
 edema-free BW, 13
 edoxaban (Lixiana), 361*b*
 eicosapentaenoic acid (EPA), 434
 electrolytes
 potassium, 21–22
 sodium, 22
 Electronic Nutrition Care Process and Terminology (eNCPT), 463
 elephant's gall, 398–399
 elevated blood pressure, 226
 emergency meal planning, 437
 considerations, 439
 expectation during emergency situation, 437
 grocery list for, 438
 preparing for emergency, 437–439
 three-day meal plan, 439
 emotional distress, 19
 empagliflozin (Jardiance), 368*b*
 enalapril maleate (Vasotec), 364*b*
 endothelial dysfunction, 225
 endotoxin, 104
 end-stage kidney disease (ESKD), 80, 139, 187, 293, 464
 enemas, 373*b*
 energy
 adult peritoneal dialysis patient, 95–98
 adult renal transplant patient, 118
 in pediatric patient, 259–265
 requirements, 36–37
 enteral formula
 defined, 319
 electrolytes and mineral content, 322
 fluid and nutrient considerations, 321–322
 fluid concentration, 321
 protein content, 321–322
 enteral nutrition (EN), 60–61, 247, 317, 327
 administration of enteral feedings, 322

- categories, nutrition content, indications, and application, 319–320*b*
- complications of feeding, 323, 324*t*
- cost containment, 321
- cyclic feedings, 322
- delivery systems, 322
- electrolytes and mineral content, 322
- enteral formula selection, 319–321
- feeding schedules, 322–323
- fluid and nutrient considerations of enteral formulas, 321–322
- fluid concentration, 321
- gastrointestinal complication, 323, 324*t*
- gastrostomy tubes, 318, 318*t*
- implementation of, 317
- intermittent feedings, 322
- jejunostomy tubes, 318, 318*t*
- mechanical complication, 323, 324*t*
- metabolic complication, 324*t*, 325
- nasogastric and nasoenteric feeding tubes, 317–318, 318*t*
- protein content, 321–322
- ready-to-use products, 322
- tube selection, 317–318, 318*t*
- enteric hyperoxaluria (EH), 298, 302
- Epidemiology of Diabetes Interventions and Complications (EDIC), 145
- Epoetin alfa (Epopgen, Procrit), 360*b*
- eprosartan (Teveten), 364*b*
- ercalcidiol, 187
- ergocalciferol, 6, 187
- erugliflozin (Steglatro), 368*b*
- erythromycin, 167
- erythropoiesis, 237
- erythropoietin (EPO), 3
- erythropoietin-stimulating agents (ESAs), 84, 237
- ESAs. *See* erythropoietin-stimulating agents (ESAs)
- essential fatty acid deficiency (EFAD), 331
- estimated average glucose (eAG), 154
- estimated glomerular filtration rate (eGFR), 18, 142, 187, 256
- etelcalcetide (Parsabiv), 84, 237, 378*b*
- ethacrynic acid (Edecrin), 362*b*
- euglycemia, 167
- euvolemic hyponatremia, 333
- Evidence Analysis Library (EAL), 456
- evidence-based practice, 459
- exenatide (Bydureon BCise), 369*b*
- Exercise in Renal Transplant (ExeRT) trial, 130
- extracellular fluid volume (ECFV), 332
- ezetimibe (Zetia), 366*b*
- ezetimide (Nexlizet), 366*b*
- familial hypomagnesemia, 293
- famotidine (Pepcid), 370*b*
- fasting plasma glucose (FPG), 19
- fat
- adult renal transplant patient, 119
 - nutrition needs/nutrition prescription, 59
 - in pediatric patient, 267–270
- fat-free mass (FFM), 11
- fat mass (FM), 11
- fat-soluble vitamins, 340
- fecal incontinence, 166, 168
- fenofibrate (Antara, TriCor), 366*b*
- ferric citrate (Auryxia), 205, 361*b*, 377*b*
- ferritin, 24–25
- ferrous fumarate (Nephro-Fer), 360*b*
- ferrous sulfate (Feosol), 360*b*
- fertility, 236
- ferumoxytol (Ferraheme), 361*b*
- fetal death, 237
- fibers
- adult peritoneal dialysis patient, 102
 - dialyzer, 65
 - dietary fiber, 163
 - gut microbiome, 448–449
- fibroblast growth factor-23 (FGF-23), 21, 185–186, 431
- finerenone (Kerendia), 380*b*
- FINE study, 349
- fish oil, omega-3 fatty acids, and α -linolenic acid, 408–410
- fishy burps, 129
- flash scanned CGM, 156
- flaxseed and flaxseed oil (*Linum usitatissimum*), 410–411
- flecainide acetate (Tambocor), 362*b*
- flexitarian, 431
- fluctuations in blood glucose, 149
- fludrocortisone (Florinef), 379*b*
- fluids
- adult peritoneal dialysis patient, 99
 - allowance, 99
 - balance, 15
 - and electrolyte balance, 3
 - electrolytes, and minerals, 332–333
 - gain. *See* interdialytic weight gains (IDWGs)
 - homeostasis, 22
 - management and adequacy of dialysis, 102
 - in pediatric patient, 277, 277*t*

- requirements, 60
- retention (edema), 22
- “flush before fill” process, 89
- fluvastatin (Livalo), 365*b*
- focal segmental glomerulosclerosis (FSGS), 5, 258
- folate, 42
- fondaparinux (Arixtra), 361*b*
- food diaries, 10
- food frequency questionnaire, 10
- food safety, adult renal transplant patient, 126
- foot ulcers and amputation, 165
- fosinopril sodium (Monopril), 364*b*
- fracture risk, 168–169
- frame size, anthropometrics and physical exam, 14
- free water intake, 56
- Fresenius Medical Care Health Plan (FMCHP), 386
- fructosamine (FA), 154–155
- Functional Assessment of Anorexia/Cachexia Therapy (FAACT) score, 9–10
- furosemide (Lasix), 362*b*

- gabapentin (Gralise, Horizant), 165, 189, 381*b*
- gallbladder disease, 167
- garlic (*Allium sativum*), 411–412
- gastrointestinal complications, 103–104
- gastric electrical stimulation, 168
- gastric residual volume (GRV), 323
- gastroesophageal reflux disease (GERD), 152, 166, 247
- gastrointestinal autonomic neuropathy (GAN), 166
- gastrointestinal complications, 298
 - adult renal transplant patient, 124–125
 - of EN, 323
- gastrointestinal-related medications
 - anorexia/appetite stimulants, 371*b*
 - antidiarrheal medications, 374*b*
 - dopaminergic-blocking agent, 370*b*
 - histamine H₂-receptor antagonists, 370*b*
 - medications to treat constipation, 371*b*–373*b*
 - proton-pump inhibitors (PPI), 371*b*
- Gastroparesis Cardinal Symptom Index, 167
- gastroparesis (GP), 166
- gastrostomy (PEG), 318
- gastrostomy tubes, 318
- gemfibrozil (Lopid), 366*b*
- genetic polymorphisms, 227
- GERD. *See* gastroesophageal reflux disease (GERD)
- Geriatric Nutrition Risk Index, 460
- gestational diabetes mellitus (GDM), 139–140, 455

- ginkgo (*Ginkgo biloba*), 412–414
- ginseng, Korean ginseng or Asian ginseng (*Panax ginseng*), American ginseng (*Panax quinquefolius*), 414–415
- glimepiride (Amaryl), 367*b*
- glipizide (Glucotrol), 367*b*
- glomerular diseases, 5
- glomerular filtration rate (GFR), 3, 18, 33, 65
- glucagon administration, 161
- glucagon-like peptide-1 (GLP-1) receptor agonist, 142
- glucocorticoid, 140
- gluconeogenesis, 147
- glucosamine and chondroitin sulfate, 415–417
- glucose exposure, 151
- glucose-lowering medications, 142
 - direct kidney effects, 146–147
- glyburide (Glynase, Micronase), 367*b*
- glycated albumin (GA), 154
- glycation, 153
- glycemia, 153, 167
- glycemia therapy goals for diabetes and kidney disease, 158*t*
- glycemic control, 60, 146, 153–158, 169, 345
 - blood glucose monitoring, 155–156
 - goals, 156–158
 - markers, hemoglobin A1c and other glycemic control, 154–155
 - measurement and monitoring, 153–154
- glycemic index, 159
- glycemic load, 159
- glycemic variability (GV), 157–158
- glycerin or bisacodyl suppositories, 373*b*
- glycoprotein IIb/IIIa Inhibitors (tirofiban, eptifibatid, abciximab), 361*b*
- good cholesterol, 22. *See also* bad cholesterol
- gout and chronic kidney disease, medications
 - allopurinol (zyloprim), 374*b*
 - colchicine (colcrys), 374*b*
 - probenecid (probalan), 374*b*
- green tea (*Camellia sinensis*), 417–418
- growth velocity, 248
- guanabenz acetate (Wytensin), 363*b*
- guanfacine hydrochloride (Tenex), 363*b*
- gut microbiome, 443
 - artificial sweeteners, 450
 - in CKD, 444
 - diet, 448
 - dysbiosis and increased intestinal permeability, 447*b*
 - dysbiosis in chronic kidney disease, 444–445
 - fat, type and amount, 450
 - fiber intake, 448–449
 - intestinal barrier and increased permeability in chronic

- kidney disease, 446–447
 - intestinal barrier and normal permeability, 443–444
 - potential interventions, 447–451
 - prebiotics and probiotics, 449
 - protein, type and amount, 449–450
- handgrip strength (HGS), 27, 36–37, 250
- Harvard School of Public Health, 301
- HbA1c, 154
- health-related quality of life scores, 173
- healthy coping, 144
- height, anthropometrics and physical exam, 13–14
- height velocity, 248
- heme iron polypeptide (Proferrin ES, Ferrimin), 360*b*
- hemodialysis (HD), 9–10, 65, 94, 149–150, 189, 199, 248, 318
- hemodynamic instability, 337
- hemodynamic stability, 82
- hemoglobin, 23–24
 - carbamylation of, 154
- hemosiderin, 24
- heparin and derivatives (Lovenox), 361*b*
- hepatic gluconeogenesis, 141
- hepatic insufficiency, 335
- hepatic protein metabolism, 18
- hepatitis C virus, 152
- herb, 396
- herbals and botanicals, adult renal transplant patient, 120–121
- herbal supplements, 396
- high-calorie supplements, 71
- high C-reactive protein (CRP), 94
- high-density lipoprotein (HDL), 22, 339
 - cholesterol (HDL-C), 129, 140
 - levels, 83
- high-protein turnover, 155
- high-turnover bone disease, 192
- HIV, 170
- home hemodialysis, adult patient on
 - benefits, 84
 - dialysate concentrate composition, 81*t*
 - dialysis modality and treatment options, 79*b*
 - dialysis prescription, 80–82
 - diet, 82–83
 - laboratory data, 83–84
 - transitional care unit, 80
 - transitional dialysis care education and intended outcomes, 81*b*
- home hemodialysis (HHD), 79–82, 237
- homocysteine levels, 129
- homocysteinemia, 228–229
- human chorionic gonadotropin (hCG), 237
- hydralazine (Apresoline), 363*b*
- hydrochlorothiazide (HCTZ) (Microzide), 362*b*
- hydrocortisone (Cortef), 379*b*
- hydroflumethiazide (Diurcardin, Saluron), 362*b*
- hydrostatic pressure, 65–66
- 1- α -hydroxylase activity, 186
- 25-hydroxyvitamin D, 41
 - deficiency, 188
 - precursors, 6
- hyperbaric oxygen treatments, 191
- hypercalcemia, 57, 84, 189
- hypercalciuria, 293, 299
- hypercatabolism, 338
- hypercholesterolemia, 27, 225
- hypercupremia, 58
- hyperglycemia, 98, 121–124, 141, 145, 149–150, 165, 167, 324*b*, 325
 - emergencies, 167
 - long-term posttransplant period, 128
- hyperhomocysteinemia, 27, 42, 129
- hyperinsulinemia, 19, 98
- hyperkalemia, 21–22, 36, 60, 125–126, 397
 - medications, 375*b*
 - potassium-removing agents, 375*b*
- hyperlipidemia, 5, 98, 258
- hypermagnesemia, 60
- hypernatremia, 56, 332
- hyperosmolar hyperglycemia syndrome, 167
- hyperoxaluria, 293, 301
- hyperparathyroidism, 20, 189
- hyperphosphatemia, 35–36, 60, 84, 187, 189–190, 201, 397
- hypertension (HTN), 3, 27, 39–40, 140, 228, 406
- hypertension management and diabetic kidney disease, 148–149
- hyperthyroidism, 19
- hypertriglyceridemia, 225, 347
- hyperuricemia, 130
- hypervolemia, 223
- hypoalbuminemia, 68, 191, 250, 258, 335
- hypocalcemia, 60, 187, 197, 339
- hypocitraturia, 290, 302
- hypoglycemia, 325, 330
 - treatment, 161
- hypokalemia, 21, 61, 72, 99, 163
- hypomagnesemia, 57, 61, 126
- hyponatremia, 56, 60
- hypophosphatemia, 61, 125

- hypophosphatemic rickets, 293
- hypotensive episodes, 66
- hypotonic hyponatremia, 332–333
- hypouricosuria, 303
- iatrogenic malnutrition, 36
- icodextrin, 90, 102
- icosapent ethyl (Vascepa), 366*b*
- ideal body weight (IBW), 257, 327
- idiopathic hypercalcuria (IH), 289
- immunosuppressants adverse effects with nutritional implications, 115*b*–116*b*
- immunosuppression therapy, 229–230
- immunosuppressive agents, 5, 259
- immunosuppressive medications, 114
- immunosuppressive therapy, 114–118
 - antirejection therapy, 114
 - antithymocyte globulin (ATG), 118
 - azathioprine (Imuran), 115*b*, 117
 - basiliximab (Simulect), 118
 - corticosteroids, 115*b*, 117–118
 - cyclosporine A (CsA) (Sandimmune, Neoral), 114, 115*b*
 - daclizumab (Zenepax), 118
 - immunosuppressants adverse effects with nutritional implications, 115*b*–116*b*
 - immunosuppressive medications, 114
 - induction therapy, 114
 - monoclonal antibodies, 118
 - mycophenolate mofetil (MMF) (CellCept), 116*b*, 117
 - sirolimus (Rapamune), 116*b*, 117
 - tacrolimus/everolimus (Prograf), 114–117, 116*b*
- impaired fasting glucose (IFG), 141
- impaired linear growth, 248
- inadequate dialysis, 66
- inadequate vascular access, 66
- in-center hemodialysis (ICHHD), 79, 465
- in-center oral nutrition supplement programs
 - mortality, 386
 - nutritional outcomes, 386
 - outcomes studies, 386
 - program description, 385–386
- incremental HD, 67
- indapamide (Lozol), 362*b*
- indirect calorimetry (IC), 16, 58
- indoxyl sulfate (IS), 104, 443
- induction therapy, 114
- inflammation, 189, 229
- inflammatory bowel disease (IBD), 290
- inhaled human insulin powder (Afrezza), 370*b*
- injury-related rhabdomyolysis, 51
- insulin, 161, 170
 - aspart (Novolog), 369*b*
 - degludec (Tresiba), 369*b*
 - detemir (Levemir), 369*b*
 - glargine (Toujeo), 369*b*
 - glulisine (Apidra), 369*b*
 - impaired tissue sensitivity, 141
 - lispro (Humalog), 369*b*
 - resistance, 141–142
 - sensitivity, 141
 - therapy, 330
- insulin-like growth factor I, 256
- insulin resistance syndrome (IRS), 141, 141*b*
- intact parathyroid hormone (iPTH) levels, 83–84
- interdialytic weight gains (IDWGs), 12–13, 321
- intermittent CGM, 156
- intermittent hemodialysis (IHD), 4, 53
- International Consensus on Posttransplantation Diabetes Mellitus Expert Committee, 152
- International Society of Renal Nutrition and Metabolism, 253–254
- Interpretive Guidelines (IG), 464–465
- intestinal permeability, dysbiosis and influential factors on, 445
- intra-abdominal space, 61
- intracellular glucose metabolism, 141
- intradialytic parenteral nutrition (IDPN), 327, 345
 - administration and management, 344–345
 - amino acids, 344
 - clinical criteria and reimbursement coverage, 342–344
 - formulation composition, 340–341, 341*t*
 - infusion and monitoring, 345
 - lipids, 345
 - role, 348–349
 - use and indications, 341–342
- intradialytic weight gain (IDWG), 71
- intraperitoneal amino acids/intraperitoneal nutrition (IPN), 346–347
 - formulations, 347–348
 - therapeutic effectiveness, 348
 - use and indication, 347
- intraperitoneal (IP) administration, 103
- intraperitoneal (IP) exposure, 150
- intraperitoneal nutrition (IPN), 327
- intravenous fat emulsion (IVFE), 61
- intravenous fluid and pain management, 290
- intravenous (IV) iron, 24
 - infusion, 103–104
 - replacement, 84

- intravenous lipid emulsion (ILE), 329, 332
 intravenous piggy backs (IVPB), 56
 iron, 24
 iron absorption capacity, 24
 iron sucrose (Venofer), 361*b*
 isbesartan (Avapro), 364*b*
 ischemic heart disease, 168
 ischemic small-vessel vasculopathy, 191
 IV calcitriol, 213
 IV fluid-containing potassium, 56–57
- jejunostomy tubes, 318, 318*t*
 feeding, 168
- Katz Activities of Daily Living, 9
 ketoacidosis, 142, 159
 keto-analogs, 199
 kidney
 anatomy, 1, 1*f*
 failure, 3–4
 functions, 3, 18
 mineral and bone metabolism in, 186*f*
 nephron, functional units of, 2*b*
 kidney-centered inflammatory syndrome, 50, 55
 Kidney Disease: Improving Global Outcomes (KDIGO), 142, 397
 AKI Guidelines, 50
 guidelines, 81
 organization, 4
 kidney disease and predialysis, 145–149
 Kidney Disease Outcomes Quality Initiative (KDOQI), 329
 Clinical Practice Guideline, 145
 Guideline, 8
 nutrition guidelines, 385
 Kidney Disease Quality of Life tool, 173
 kidney failure, 293
 kidney healthy plate, 43*f*
 kidney replacement therapy (KRT), 4, 65, 87, 149–152, 245, 321, 327
 hemodialysis, 149–150
 peritoneal dialysis, 150–152
 transplantation and hyperglycemia, 152
 Kidney Stone Belt, 294
 kidney stones, dietary factors
 calcium, 294
 fluid intake, 294
 magnesium, 295
 oxalate, 294
 phytate, 295
 potassium, 295
 protein, 295
 sodium, 294–295
 vitamin and herbal supplements, 295–296
 kidney stones, nutritional management
 atherosclerosis/cardiovascular disease, 297
 calcium stones, 299–303
 chronic kidney disease, 297
 cystine stones, 305–306
 diabetes mellitus, 296–297
 diagnosis, 290–291
 epidemiology, 289
 gastric bypass surgery, 298
 gastrointestinal disease, 298
 general diet guidelines, 307*b*
 general nutrition assessment, 299
 hypertension, 297
 medical and diet management per stone type, 299
 metabolic syndrome, 296–297
 normal values, 24-hour urine collection, interpretation and causes, 292*t*–293*t*
 nutrient recommendation for, 306*t*
 nutritional and medical recommendation, 307*b*
 obesity, 296–297
 pathophysiology, 289–290
 risk factors, 293–296, 296*b*
 struvite/staghorn calculi, 306
 surgical management, 298
 symptoms, 290
 uric acid stones, 303–305
 kidney toxin, 58
 kidney transplantation, 80
 and cardiovascular disease, 229–230
 klotho, 186
 klotho hormones, 185
 knee height caliper, 13
 KRT/CRRT fluid removal, 55
 Kt/V, 25
- labetalol (Trandate), 363*b*
 lactic acidosis, 128
Lactobacillus species, 443
 lacto-ovo vegetarian, 431
 lactulose, 372*b*
 lanthanum carbonate (Fosrenol), 204–205, 376*b*
 laparoscopic pyloroplasty, 168
 lean body mass (LBM), 36–37, 257
 left ventricular hypertrophy (LVH), 168

- levocarnitine, 334–335
- lidocaine, 165
- lifestyle modification, 171. *See also* bariatric surgery
- lily of the desert, 398–399
- linaclotide (Linzess), 372*b*
- linagliptin (Tradjenta), 368*b*
- lingering bad taste, 129
- lipase enzyme, 339
- lipid-lowering medications, 22, 71
- lipids, 22, 331–332, 339, 345
 - control, 191
 - profiles, 128–129
- liraglutide (Victoza, Saxenda), 369*b*
- lisinopril (Prinivil; Zestril), 364*b*
- liver failure, 19
- lixisenatide (Adlyxin), 369*b*
- lixivaptan, 380*b*
- long-term corticosteroid therapy, 129
- long-term posttransplant period, 127–131
 - anemia, 130
 - cancer, 130
 - chronic allograft nephropathy, 131
 - dyslipidemia, 128–129
 - hyperglycemia, 128
 - hyperuricemia, 130
 - nephrolithiasis, 130–131
 - nutrition goals, 127
 - obesity, 127–128
 - osteoporosis, 129
 - physical activity, 129–130
 - pregnancy, 130
- loperamide hydrochloride (Imodium), 168, 374*b*
- losartan (Cozaar), 364*b*
- losing lean body mass (LBM), 13
- lovastatin (Mevacor), 365*b*
- low-density lipoprotein cholesterol (LDL-C), 129, 225
- low-density lipoprotein (LDL), 22
- lower-extremity amputation (LEA), 166
- Lowe syndrome, 293
- low-fat protein sources, 162
- low-turnover bone disease, 192–193
- lubiprostone (Amitiza), 372*b*
- macroalbuminuria, 5, 145
- macronutrient distribution, 158–159
- magnesium, 191
 - in acute kidney injury, 57
 - mineral and bone disorders and kidney disease, 197–198
- magnesium-based binders, 204
- magnesium carbonate (MagneBind), 204, 377*b*
- magnesium citrate, 372*b*
- magnesium hydroxide (Milk of Magnesia), 372*b*
- maintenance dialysis (MD), 257
- maintenance HD (MHD), 10
- Making Choices Meal Planning for Diabetes and CKD, 161
- malignancy, 19
- malnutrition, 8, 19, 34–35
 - diabetes-related complications, comorbidities and concerns, 170
 - nutrition management in CKD stages 1 through 5, 34–35
 - peritoneal dialysis, adult patient on, 104–105
- malnutrition-inflammation score (MIS), 26–27, 229, 327, 387
- marked inflammatory response, 8
- massive proteinuria, 155
- MBD. *See* mineral bone disorder (MBD)
- meal planning, 160, 435*b*
- meal-related protein synthesis, 167
- mechanical bowel obstruction, 61
- mechanical complications of EN, 323
- medial calcific sclerosis, 225
- medical nutrition therapy (MNT), 3, 8, 33–34, 158–164, 245
 - American Diabetes Association General Goals Of Medical Nutrition Therapy, 158
 - carbohydrate management, dietary strategies for, 159–161
 - counseling considerations, 163–164
 - definition, 455
 - dietary fat, 162
 - dietary fiber, 163
 - dietary protein, 161–162
 - and evidence-based guides to practice, 456
 - hypoglycemia treatment, 161
 - macronutrient distribution, 158–159
 - nutrition evaluation and monitoring, 455
 - potassium considerations, 163
 - reimbursement for, 457–458
 - sodium and fluid considerations, 163
 - sugar and nonnutritive sweeteners, 162–163
- Medicare fee-for-service, 458
- medications for kidney disease, 359
 - anemia, 360–361
 - antigout agents, 374
 - cardiovascular disease (CVD), 360–367
 - chronic kidney disease, 375–378
 - diabetes, 367–370

- gastrointestinal-related medications, 370–374
hyperkalemia, 375
medications with nutritional implications, 379
renal vitamins, 382–383
specific kidney diseases and conditions, 379–381
- Mediterranean diets, 38, 159, 200, 431
- megestrol acetate (Megace), 371*b*
- membrane pore size, 65–66
- mental illness, 173
- metabolic acidosis, 3, 35, 141, 162, 191–192, 333
- metabolic complications of EN, 325
- metabolic surgery, 172
- metabolic syndrome (MS), 141, 289
- metformin (Glucophage, Riomet), 142, 169, 367*b*
- methoxy polyethylene glycol-epoetin beta (Micera), 360*b*
- methyclothiazide (Enduron, Aquatensen), 362*b*
- methylcellulose (Citrucel), 371*b*
- methyl dopa (Aldomet), 363*b*
- methyl naltrexone (Relistor), 373*b*
- metoclopramide (Reglan), 167, 370*b*
- metolazone (Zaroxolyn), 362*b*
- metoprolol succinate (Toprol XL), 363*b*
- metoprolol tartrate (Lopressor), 363*b*
- microalbuminuria, 5, 145
- micronutrients
in acute kidney injury, 57–58
adult dietary guidelines, 382*t*
and supplements, 41–42
- microvascular and macrovascular complications, 164
- mid-arm muscle circumference (MAMC), 36–37
- midodrine (ProAmatine), 365*b*
- midparental height, 248
- mid-upper arm circumference (MUAC), 249
- miglitol (Glyset), 368*b*
- migraines, 406
- mild asymptomatic hypermagnesemia, 57
- mild hyperkalemia, 72
- milk thistle (*Silybum marianum*), Lady's thistle, 418–419
- minerals
oil-oral, 373*b*
pregnancy, 240
- mineral and hormonal abnormalities
abnormal laboratory markers in, 189*t*
calcium, 187
parathyroid hormone, 188–189
phosphorus, 188
vitamin D, 187–188
- mineral bone disorder (MBD), 168–169
calcium, 214
- disordered physiology and progression of disease, 186–191
- kidney transplant, 213–215
- laboratory monitoring, frequency of, 198*t*
- parathyroid hormone (PTH), 214
- phosphorus, 214
- physiology, 185–186
- prevention and management, 194–215
- renal bone disease, causes and types, 191–193
- renal osteodystrophy, 193–194
- vitamin D, 214
- mineralization, 194
- minimal change disease, 5
- minoxidil (Lonite), 363*b*
- mirtazapine (Remeron), 371*b*
- MIS. *See* malnutrition-inflammation score (MIS)
- mixed-uremic bone disease, 193
- moexipril (Univasc), 364*b*
- Mogensen, 145
- Mönckeberg medial calcific sclerosis, 225
- monoclonal antibodies, 118
- monounsaturated fatty acids (MUFA), 331
- motivational interviewing (MI), renal dietitian, 472, 472*b*
- M-Tool: Michigan's Malnutrition Diagnostic Tool, 254
- MUAC. *See* mid-upper arm circumference (MUAC)
- multiorgan dysfunction (MOD), 58
- multitrace element (MTE) preparations, 58
- multivitamin-mineral supplements, 41
- multivitamins, 398
- muscles
atrophy, 172
catabolism, 35
dysfunction, 250
loss, 15
wasting, 95
- mycophenolate mofetil (MMF) (CellCept), 116*b*, 117
- myocardial fibrosis and calcification, 225
- myocardial infarction (MI), 190, 297
- nadolol (Corgard), 363*b*
- nalfurafine, 381*b*
- naloxegol (Movantik), 373*b*
- nasal tube feeding, 168
- nasogastric and nasoenteric feeding tubes, 317–318, 318*t*
- nateglinide (Starlix), 367*b*
- National Academy of Medicine, 159
- National Glycohemoglobin Standardization Program (NGSP), 154

- National Health and Nutrition Examination Survey (NHANES), 188
- National Institute for Health and Care Excellence guidelines, 237
- National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-KDOQI), 4, 10, 33, 66, 147
- National Kidney Foundation (NKF), 18, 227–228, 456
- natural *vs.* added phosphorus, 200–202
- naturallyte, 81
- nausea, 247, 324*b*
- NCP. *See* Nutrition Care Process (NCP)
- NCPM. *See* Nutrition Care Process Model (NCPM)
- nebivolol (Bystolic), 363*b*
- needle placement (recirculation), 66
- negative acute-phase reactants, 55
- nephrocalcinosis, 293
- nephrolithiasis, 130–131
 - alcohol consumption and, 305
 - calcium intake and excretion, 300
 - dietary factors, 294, 297
 - hypertension, 297
 - long-term posttransplant period, 130–131
 - obesity epidemic, 289
 - prevalence, 289
 - uric acid, 304
- nephrology nutrition, 457
- nephrotic syndrome (NS), 5–6, 19, 147, 155
- neutral protamine Hagedorn (NPH), 150–151
- new-onset DM after transplantation (NODAT), 152
- NGSP-certified assay methods, 154
- niacinamide, 378*b*
- nicotinic acid (Niaspan), 367*b*
- nitrogen balance, 56
- nitroprusside (Nitropress), 363*b*
- nizatidine (Tazac, Axid), 370*b*
- nocturnal hemodialysis (NHD), 79
- nocturnal HHD (NHHD), 79–82
- nocturnal intermittent hemodialysis (NIHD), 67
- nocturnal intermittent peritoneal dialysis (NIPD), 258
- nonalbuminuric renal impairment, 145
- non-calcium-based phosphate binders, 191, 204, 205
- nonfatal myocardial infarction, 71
- noni (*Morinda citrifolia*), 419–420
- nonjudgmental patient-centered communication, 171
- nonnutritive sweeteners, 162–163
- nonsteroidal antiinflammatory agents, 72
- normalized protein catabolic rate (nPCR), 10, 66, 68, 94, 344
- normalized protein nitrogen appearance (nPNA), 25, 91, 344
- nucleation, 290
- nutrinal amino acid, 347
- nutrition
 - counseling, 94, 471
 - documentation, 321
 - education, 257
 - support monitoring guidelines, 346*b*
 - therapy, 67, 303
- nutrition assessment tools, 8
 - handgrip strength, 27
 - malnutrition-inflammation score (MIS), 26–27
 - protein energy wasting (PEW), 27
 - subjective global assessment (SGA), 26
- Nutrition Care Process Model (NCPM), 464*f*
 - in clinical practice, 465
 - and conditions for coverage mandates, 465
 - 24-hour diet recall, initial nutrition assessment, 467*b*
 - in-center hemodialysis, 466*f*
 - interdisciplinary team (IDT), 465
 - in nephrology nutrition, 464–465
 - nutrition diagnoses and plan of care, 467*b*
 - sample documentation, 465
 - terminology, 465
 - three-month reassessment documentation, 468*b*
- nutrition care process (NCP), 8, 455, 463
- terminology (NCPT), 463
- tutorial modules, 465
- nutrition-focused physical exam (NFPE), 8, 15, 250–253
- nutritive sweeteners, 162–163
- obesity, 27, 35, 98
 - diabetes-related complications, comorbidities and concerns, 170–172
 - kidney stones, nutritional management, 296–297
 - long-term posttransplant period, 127–128
 - nephrolithiasis, 289
 - peritoneal dialysis, adult patient on, 102–103
 - pretransplant period, 112–113
- oligohydraminos, 237
- oliguria, 4, 60
- omega-3 acid ethyl esters (Lovaza), 366*b*
- omega-3 (fish oil) fatty acids, 226, 302, 434–435
- omega-9 (olive oil) fatty acids, 226
- oncotic pressure, 19, 89
- on-dialysis supplementation, 68
- oral glucose tolerance test (OGTT), 152
- oral health and dental disease, 169–170
- oral iron, 24, 103–104

- oral nutrition supplements (ONS), 60, 385
 evidence on oral nutrition supplement programs, 387
 in-center oral nutrition supplement programs, 385–386
 patients on dialysis, 385
 practice, 387–393
 program outcomes studies, 390^t
- oral phosphorus supplements, 125^t
- osmotic agents, 89, 96–98
- osmotic gradient, 151
- osmotic laxatives, 168
- osteoblast-like cells, 190
- osteoblast markers, 194
- osteomalacia, 193
- osteoporosis, 169, 193
 immunosuppressive drugs, 130
 long-term posttransplant period, 129
 renal bone disease, causes and types, 193
 uremic, 193
- oxalate, 293
- oxalate-containing foods, 301
- Oxalobacter formigenes, 298
- oxidant stress, 67
- oxidative stress, 165
- oxymetholone (Anadrol-50), 379^b
- pain medicines, 168
- pancreas-kidney transplant, 152
- pancreatic enzymes, 168
- pancreatic insufficiency, 19
- pancreatic tumors, 19
- parathyroidectomy, 191
 mineral and bone disorders and kidney disease, 212–213
 with reimplantation, 212
 subtotal, 212
 total, 212–213
- parathyroid gland, 185
- parathyroid hormone (PTH), 20, 141, 237, 431
 control, 83–84
 mineral and bone disorders and kidney disease, 210–211, 214
 mineral and hormonal abnormalities, 188–189
- parathyroid hyperplasia, 187
- parenteral multivitamin, 62
- parenteral nutrition (PN), 58, 61–62, 127, 168, 327
 acute kidney injury (AKI) and, 337
 administration and management of intradialytic, 344–346
 Calorie Contribution of, 329^t
 chronic kidney disease (CKD) and, 327–329
 clinical criteria and reimbursement coverage, 342–344
 intradialytic, 340–342
 intraperitoneal amino acids/intraperitoneal nutrition (IPN), 346–348
 monitoring patients on, 336^t
 protein-energy wasting and outcomes, 348–349
 solution for adults, 328^b–329^b
- paricalcitol (Zemplar), 378^b
- patient-based education, renal dietitian, 471
- patient history
 appetite assessment tools, 9–10
 diet history, 10
 medical and psychosocial history, 9
- patient motivation, 161
- patiomer (Valtesa), 375^b, 433
- P-cresyl sulfate (PCS), 104, 443
- PD. *See* peritoneal dialysis (PD)
- pediatric dietary restrictions, 257
- pediatric malnutrition, 460
- pediatric patient, kidney disease in
 anthropometrics, 247–250
 body mass index, 249
 chronic kidney disease, 257–258
 defining pediatric malnutrition, recommended domains for, 253^b
 dialysis, 258
 edema assessment, 253^t
 feeding difficulties, 247
 length/height and linear growth, 248
 malnutrition and protein-energy wasting, 253–254, 460
 mid-upper arm circumference, 249–250
 nephrotic syndrome, 258
 nutritional status, assessment, 246–250
 nutrition-focused physical exam (NFPE), 250–253
 nutrition intervention, 256–259
 nutrition management, 259–277
 physical exam, 251^b–252^b
 Texas Children's Hospital Pediatric Malnutrition Tool, 255^t
 transplant, 258–259
 treating growth failure, 256
 weight, 248–249
 weight-for-length, 249
- Peginesatide (Omontys), 360^b
- penbutolol sulfate (Levatol), 363^b
- percutaneous endoscopic gastrostomy (PEG), 318
- percutaneous nephrolithotomy, 298
- perindopril (Aceon), 364^b
- periodontal gum disease, 170
- periodontal inflammation, 169

- peripheral parenteral nutrition (PPN), 327, 337
- peripheral vascular disease (PVD), 148
- peritoneal dialysate, 54
- peritoneal dialysis (PD), 11, 53, 87, 150–152, 155, 192, 237
 - adequacy of dialysis, 91
 - adequacy targets, 92*b*–93*b*
 - diabetes, 103
 - equilibration rates, 91
 - fluid management and adequacy of dialysis, 102
 - gastrointestinal concerns, 103–104
 - history, 88
 - KDOQI adequacy guidelines, 93*b*
 - malnutrition, 104–105
 - nutrient recommendations, 94–102, 101*b*–102*b*
 - nutrition assessment, 94
 - obesity, 102–103
 - peritoneal membrane, 90–91, 91*b*
 - peritonitis, 105–106
 - process, 89–90, 89*f*
 - rates, 80
 - side effects and and potential interventions, 106*b*
 - solutes and fluid, removal, 91
 - types, 88*b*
- peritoneal equilibration test (PET), 91, 151
- peritoneal membrane
 - classifications, 91*b*
 - peritoneal dialysis, adult patient on, 90–91
- peritoneal protein losses, 94
- peritonitis, 61, 105–106
- personal eating awareness, renal dietitian, 473
- pesco vegetarian, 431
- PET. *See* peritoneal equilibration test (PET)
- PEW. *See* protein energy wasting (PEW)
- phenols, 443
- phosphate
 - buffers intracellular fluid, 3
 - in medications and supplements, 202
 - phosphate transporter-1, 206
 - phosphate transporter-2, 206
 - sodium phosphate-2*b*, 206
 - tenapanor, 206–207
 - transport inhibitors, 206–207
- phosphate binders, 21, 191, 203*t*, 337
 - calcium-based, 189
 - calcium-containing, 168
 - chronic kidney disease (CKD), 375*b*
 - mineral and bone disorders and kidney disease, 202–206
 - non-calcium-based, 204
- phosphorus
 - in acute kidney injury, 57
 - adult peritoneal dialysis patient, 100
 - calcium and vitamin D, 270–274, 273*t*
 - CKD-MBD, 21
 - control, mineral and bone disorders and kidney disease, 209
 - mineral and bone disorders and kidney disease, 198–202, 214
 - mineral and hormonal abnormalities, 188
 - natural *vs.* added, 200–202
 - removal, 208
 - removal during dialysis, 208
 - restriction and mortality, 199
 - physical activity, long-term posttransplant period, 129–130
 - physical conditioning and exercise, 172
 - pindolol (Visken), 363*b*
 - pioglitazone (Actos), 368*b*
 - pituitary dysfunction, 19
 - Plan-Do-Study-Act methodology of CQI, 459
 - plant-based protein, 162
 - polycystic kidney disease, 15
 - polyethylene glycol (Miralax), 372*b*
 - polysaccharide iron complex (Niferex, Nu-Iron), 360*b*
 - polythiazide (Renese), 362*b*
 - polyuria, 339
 - post-dialysis BUN, 66
 - post hoc subgroup analysis, 54
 - postprandial glucose monitoring, 155
 - postrenal AKI, 51
 - posttransplant, 8. *See also* long-term posttransplant period
 - mineral bone disorders (MBD), 213
 - monitoring, 152
 - nutrition concerns, 121–127
 - quality of life, 245
 - posttransplantation diabetes (PTDM), 152
 - posttreatment fatigue, 150
- potassium, 56
 - in acute kidney injury, 56–57
 - adult peritoneal dialysis patient, 99
 - adult kidney transplant patient, 120
 - binding medications, 72
 - considerations, 163
 - diffuse, 89
 - excretion, 39
 - free lactated Ringer's solution, 90
 - in pediatric patient, 276–277
 - and phosphorus, 433–434
 - restriction, 82
 - salt form, 56–57
 - sparing diuretics, 72

- potassium citrate, 299–300, 303
- potential renal acid load (PRAL), 302
- PRAL. *See* potential renal acid load (PRAL)
- pravastatin (Pravachol), 365*b*
- prazosin hydrochloride (Minipres), 363*b*
- prealbumin, 55
- prebiotics. *See also* probiotics
and probiotics, 449
and probiotic supplementation, 300
- prediabetes, 140*b*, 141–142
- predialysis, 145–146
- prednisolone (Omnipred), 379*b*
- prednisone (Rayos, Deltasone), 379*b*
- pre-end-stage renal disease (pre-ESRD), 455
- pregabalin (Lyrica), 381*b*
- pregnancy
breastfeeding, 240–241
case study, 241–243
and chronic kidney disease, 236–243
complications, 130
dialysis regimen, 237–239
long-term posttransplant period, 130
management guidelines for, 238*b*
medical considerations, 236–237
minerals, 240
protein and energy, 239
vitamin, 239–240
weight gain, 240
- prerenal AKI, 4, 51
- pretransplant period, 112–114
evaluation, 112
frailty, 112
Fried Frailty Index, 112, 113*b*
low BMI, 113–114
obesity, 112–113
registered dietitian nutritionists (RDNs), 112
transplant candidates selection, 114
- primary hyperoxaluria (PH), 289–290
- probenecid (Probalan), 374*b*
- probiotics, 302, 449. *See also* prebiotics
- problem-solving approach, 158
- progressive renal decline, 145
- proinflammatory cytokines, 54
- prokinetic agents, 247
- propofol, 339
- propranolol hydrochloride (Inderal; Inderal LA), 363*b*
- protective sensation, loss, 165–166
- protein-energy malnutrition (PEM), 22, 34, 94, 342, 347
- protein energy wasting (PEW), 14, 27, 34, 53, 55, 67, 94, 249
markers, 327, 385
syndrome, 341
- protein(s), 259–265, 431–433
in acute kidney injury, 55–56
adult peritoneal dialysis patient, 95
adult renal transplant patient, 118
- and phosphorus-containing foods, 39
catabolism, 66
-controlled diet, 41
degradation, 147
-derived nitrogenous waste products, 35
energy and diabetic kidney disease progression, 147–148
energy and pregnancy, 239
and fat intakes, 161
-losing enteropathy, 19
-losing states, 19
losses, 95
loss into dialysate, 151
modulars, 322
nutrition, 94
nutrition needs/nutrition prescription, 59
in pediatric patient, 265–267
powders and nutritional supplements, 162
requirements, 35–36
type and amount, 449–450
- proteinuria, 5, 258
- proteolytic bacteria, 443
- prucalopride (Prudac, Motegrity), 372*b*
- psychological and mental health issues, 172–173
- psyllium (Metamucil Psyllium), 371*b*
- pulmonary edema, 168
- pyloric dysfunction, 167
- pyridoxine, 42
- pyrophosphate, 190
- QAPI. *See* quality assessment and performance improvement (QAPI)
- quality assessment and performance improvement (QAPI), 458
- Quality Improvement Program (QIP), 81, 458
- quality of life (QOL), 34, 67, 80, 103
- quinapril hydrochloride (Accupril), 364*b*
- racial-ethnic subgroups, 14
- radiation-induced enteritis, 61
- ramipril (Altace), 364*b*
- randomized controlled trials (RCT), 387
- ranitidine (Zantac), 370*b*

- rapid-acting insulin, 167
- rapid discontinuation of prednisone (RDP), 117–118
- RDN. *See* registered dietitian nutritionists (RDNs)
- ready-to-use EN products, 322
- real-time CGM devices, 156
- recombinant human growth hormone (rhGH), 256
- recumbent length, 247
- red blood cell (RBC) turnover, 140
- Reducing Deaths due to Oxidative Stress (REDOX) study, 54
- refeeding syndrome (RFS), 61, 324*b*, 325, 331
- registered dietitian nutritionists (RDNs), 8, 33–34, 65, 82, 94, 256, 299, 317, 322, 325, 330, 457–458
- anemia management, 231
 - and behavior counseling skill, 473
 - calcium, phosphorus and parathyroid hormone, 231
 - in CVD, 230–232
 - diabetes management, 232
 - exercise, 233
 - fat intake, 231
 - hypertension management, dietary aspects, 231–232
 - protein and energy intake in patients, 230–231
 - smoking cessation, 232
 - weight management, 232
- religious and cultural beliefs, 9
- renal bone disease, causes and types, 191–193
- bone disease via biopsy, 192
 - chronic metabolic acidosis, 191–192
 - dialysis population, 192
 - high-turnover bone disease, 192
 - low-turnover bone disease, 192–193
 - metabolic acidosis, 191–192
 - mixed-uremic bone disease, 193
 - osteoporosis, 193
 - renal osteodystrophy, 192
- renal dietitian, counseling and communication skills. *See also* registered dietitian nutritionists (RDNs)
- attitude, 470–471
 - behavior-change skills, 471
 - change conversations, stages, 472*b*
 - chronic kidney disease (CKD), 470
 - cognitive behavior therapy (CBT), 472–473, 473*b*
 - motivational interviewing (MI), 472, 472*b*
 - nutrition counseling, 471
 - patient-based education, 471
 - personal eating, awareness of, 473
 - registered dietitian nutritionist and behavior counseling skill, 473
 - skills and tools for, 470–473
 - transtheoretical model, 471–472
- Renal Dietitians Dietetic Practice Group (RPG), 475
- renal-friendly oral nutrition supplement products, 388*t*
- renal gluconeogenesis, 153
- renal multivitamin supplementation, 82–83
- renal nutrition practitioner, practice for, 457
- renal osteodystrophy, 192–194
- renal replacement therapy replacement fluids, 340*t*
- renal tubular acidosis (RTA), 290
- renal vitamins, 382–383
- renin-angiotensin aldosterone system, 3, 141
- repaglinide (Prandin), 367*b*
- residual kidney function (RKF), 67, 87, 208, 245
- resources for kidney disease, 476*b*–479*b*
- Council on Renal Nutrition of the National Kidney Foundation, 475
 - Renal Dietitians Dietetic Practice Group (RPG), 475
- resting energy expenditure (REE), 16, 36
- restricted intrauterine growth, 237
- retinol (vitamin A), 422–424
- retrospective CGM, 156
- rhabdomyolysis, 56
- risk-based screening, 140
- rivaroxaban (Xarelto), 361*b*
- rosiglitazone (Avandia), 368*b*
- roxadustat, 361*b*
- R-tPA (alteplase, tenecteplase) (TPA, Cathflo Activase), 362*b*
- sacubitril/valsartan (Entresto), 365*b*
- salivary dysfunction, 170
- salt-wasting condition, 257
- saw palmetto (*Serenoa repens*), 420–421
- saxagliptin (Onglyza), 368*b*
- SBW. *See* standard body weight (SBW)
- secondary hyperparathyroidism (SHPT), 187
- Second Cancer Prevention Survey (CPS II), 293
- self-care behaviors, 144
- self-efficacy, 471
- self-management behavior and medical nutrition therapy, 42–44
- self-monitoring of blood glucose (SMBG), 153
- semaglutide (Ozempic, Rybelsus), 369*b*
- sennosides (Senokot, ExLax), 372*b*
- sepsis, 55, 61
- serum albumin, 19, 335, 349
- serum calcium, 189, 197
- serum creatinine, 18
- serum ferritin, 24
- serum glucose, 19–20
- serum potassium (K), 82, 149

- serum prealbumin, 19, 335
- serum proteins, 18–19
- serum triglycerides, 331, 345
- sevelamer, 22, 74, 191, 204–205, 272
- sevelamer carbonate (tablets or powder) (Renvela), 204, 376*b*
- sevelamer hydrochloride (Renagel), 74, 204
- sevoflurane (Ultane), 399
- SGA. *See* subjective global assessment (SGA)
- short chain fatty acids (SCFA), 443
- short stature, 248
- simvastatin (Zocor), 365*b*
- sirolimus (Rapamune), 116*b*, 117
- sitagliptin (Januvia), 368*b*
- skeletal muscle
 - glucose uptake, 141
 - wasting, 55
- skinfold thickness, 15, 250
- slow continuous ultrafiltration (SCUF), 53
- sodium, 10, 434
 - in acute kidney injury, 56
 - adult peritoneal dialysis patient, 98–99
 - and fluid considerations, 163
 - and fluids, adult renal transplant patient, 119–120
 - in pediatric patient, 274–276, 275*t*
 - restriction, 82
- sodium bicarbonate supplementation, 299–300, 303, 381*b*
- sodium ferric gluconate (Ferrlecit), 361*b*
- Sodium-glucose cotransporter, 128
- sodium-glucose cotransporter inhibitor (SGLT2i), 142
- sodium-hydrogen exchanger (NHE3) activity, 206–207
- sodium phosphate-2b, 206
- sodium phosphate-2b inhibitors, 206
- sodium polystyrene sulfonate (Kayexalate), 72, 375*b*, 433
- sodium zirconium cyclosilicate (Lokelma), 375*b*, 433
- somatostatin, 168
- sotalol (Betapace), 363*b*
- soybean oil (SO)-based emulsion, 331
- soy oil-based IVFE, 61
- spironolactone (Aldactone), 56–57, 362*b*
- St John's wort (*Hypericum perforatum*), 421–422
- standard body weight (SBW), 11
- standard deviation scores (SDS), 247
- starvation-related malnutrition, 54
- sterile hypertonic solution, 90
- steroids used with chronic kidney disease
 - anabolic-androgenic steroids, 379*b*
 - corticosteroids, 379*b*
- stimulant laxatives, 399
- Stone Belt, 289
- stool softener, 373*b*
- stress hormones and inflammatory cytokines, 149
- stroke, 148. *See also* cardiovascular disease (CVD)
- strong and good grade, 397*b*
- struvite/staghorn calculi, 306
- stunting, 248
- subcutaneous fat loss, 15, 55
- subjective global assessment (SGA) score, 26, 68, 94, 327, 387
- suboptimal dietary intake, 13
- subtotal parathyroidectomy, 212
- sucralfate (Carafate), 337
- sucroferric oxyhydroxide (Velphoro), 191, 205, 377*b*
- sugar and nonnutritive sweeteners, 162–163
- supplements, 434–435. *See also* dietary supplements
- sustained low-efficiency dialysis (SLED), 53
- syndrome of inappropriate antidiuretic hormone (SIADH), 332
- tacrolimus/everolimus (Prograf), 114–117, 116*b*
- telmisartan (Micardis), 364*b*
- tenapanor (Ibsrela), 206
- terazosin hydrochloride (Hytrin), 363*b*
- tesevatinib, 380*b*
- Texas Children's Hospital Pediatric Malnutrition Tool, 254, 255*t*
- thiamin (vitamin B1), 424–425
- thiazide diuretics, 299
- thiazolidinediones, 169
- 3-day food records/diary, 10
- tidal peritoneal dialysis (TPD), 88, 88*b*, 258
- time of diagnosis of type 2 diabetes (T2DM), 139
- timolol maleate (Biocarden), 363*b*
- tolvaptan (Jynarque), 365*b*, 380*b*
- torseamide (Demadex), 362*b*
- total parathyroidectomy, 212–213
- total parathyroidectomy with reimplantation, 212
- total serum calcium, 197
- TPD. *See* tidal peritoneal dialysis (TPD)
- trandolapril (Mavik), 364*b*
- transferrin, 24
- transferrin saturation, 25
- transitional care unit (TCU), 80
- transitional dialysis care, 80, 81*b*
- transplantation and hyperglycemia, 152
- transplant herbs and botanicals, 121*t*–123*t*
- transthyretin, 19
- triamcinolone methylprednisolone (Kenalog), 379*b*

- triamterene (Dyrenium), 362*b*
 triceps skinfold, 15
 triglyceride, 22
 trust, 470–471
 tube
 clog, 324*b*
 dislodgment, 324*b*
 feeding, 105
 tubulointerstitial AKI, 51
 tumor necrosis factor α , 189
 24-hour food recall, 10
 24-Hour urine collection, 10, 292*b*–293*b*
 adequacy, 291
 interpretation, 291, 292*b*–293*b*
 urine collection, 290–291
 type 1 and type 2 diabetes mellitus, 139–140, 142–143
- UBW. *See* usual body weight (UBW)
 ultrafiltration (UF), 89, 150
 unbound calcium, 202–204
 United Kingdom Prospective Diabetes Study (UKD PS), 145
 United States Renal Data System (USRDS), 37, 79, 87, 190
 urea kinetic modeling (UKM), 25
 urea kinetic model (UKM), 66
 urea nitrogen appearance (UNA), 56
 urea reduction ratios (URRs), 26, 83
 uremia, 3
 uremic osteoporosis, 193
 uremic solutes, 89
 uremic toxins, 35, 84
 ureteroscopy, 298
 uric acid stones
 medical management, 303–304
 nutritional management, 304–305
 urinary citrate, 302
 urinary phosphaturic effect, 186
 urinary tract infection (UTI), 290
 urine, 1
 sodium concentrations, 51
 supersaturation (SS), 289
 urine urea nitrogen (UUN), 10
 URRs. *See* urea reduction ratios (URRs)
 usual body weight (UBW), 11
- vascular abnormalities, 165
 vascular calcification (VC), 40, 189
 vascular endothelium, 225
 vascular permeability, 19
 vegan, 431
 vegan and lacto-ovo vegetarian foods, 432*t*
 vegetarian, vegan, or plant-based diets, 431
 calories, 434
 potassium and phosphorus, 433–434
 protein, 431–433
 sodium, 434
 supplements, 434–435
 vegetarian low-protein diet, 41
 velosulin, 369*b*
 venglustat (Ibiglustat), 380*b*
 venovenous hemodiafiltration, 4
 venting gastrostomy, 168
 Visual Analog Scale (VAS), 9
 vitamins
 adult peritoneal dialysis patient, 101, 101*b*–102*b*
 adult renal transplant patient, 120
 and minerals, 101, 101*b*–102*b*, 120
 pregnancy, 239–240
 supplementation recommendations, 42*t*
 and trace elements, 334
 vitamin A, 58, 75*t*
 vitamin B, 75*t*
 vitamin B7. *See* biotin
 vitamin C, 75*t*
 vitamin D, 141
 activation, 3
 analogs, 237
 CKD-MBD, 20
 deficiency, 188
 insufficiency, 6
 levels, 83–84
 mineral and bone disorders and kidney disease, 209–210
 mineral and hormonal abnormalities, 187–188
 receptor (VDR), 185
 therapy, 168
 vitamin D2, 187
 vitamin K, 75*t*
 voclosporin (Lupkynis), 380*b*
 vomiting, 247, 324*b*
- waist circumference, 14–15
 waist-to-hip ratio (WHR), 232
 warfarin (Coumadin), 191, 361*b*, 399

weight-for-length, 247, 249
weight gain, 82, 240
weight loss, 11, 153
weight management, 171
Western diet, 35–36
whole-body protein synthesis, 348
whole-diet approach, 159
World Health Organization (WHO) Child Growth Standards, 247

Xanthine oxidase inhibitors, 303

z-scores (ZS), 247

SAMPLE
Not for Print
Or Sale